<!DOCTYPE html>
<html prefix='og: http://ogp.me/ns#'>
<head>
<link href='../favicon.png' rel='icon' type='image/png'>
<link href='../assets/apple-touch-icon.png' rel='apple-touch-icon' sizes='72x72' type='image/png'>
<link href='trials.html' rel='canonical'>
<meta content='text/html;charset=utf-8' http-equiv='Content-Type'>
<meta content='IE=edge,chrome=1' http-equiv='X-UA-Compatible'>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-6.newrelic.com","errorBeacon":"bam.nr-data.net","licenseKey":"df7d6b7270","applicationID":"3316025","transactionName":"cl5cF0cLWlsDEEsHWF9FVw1BS0JFDwMIO0dQVlc=","queueTime":0,"applicationTime":1391,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-515.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(n,t,e){function r(e){if(!t[e]){var o=t[e]={exports:{}};n[e][0].call(o.exports,function(t){var o=n[e][1][t];return r(o?o:t)},o,o.exports)}return t[e].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<e.length;o++)r(e[o]);return r}({QJf3ax:[function(n,t){function e(n){function t(t,e,a){n&&n(t,e,a),a||(a={});for(var u=c(t),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,e);return s}function a(n,t){f[n]=c(n).concat(t)}function c(n){return f[n]||[]}function u(){return e(t)}var f={};return{on:a,emit:t,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=n("gos");t.exports=e()},{gos:"7eSDFh"}],ee:[function(n,t){t.exports=n("QJf3ax")},{}],gos:[function(n,t){t.exports=n("7eSDFh")},{}],"7eSDFh":[function(n,t){function e(n,t,e){if(r.call(n,t))return n[t];var o=e();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(n,t,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return n[t]=o,o}var r=Object.prototype.hasOwnProperty;t.exports=e},{}],D5DuLP:[function(n,t){function e(n,t,e){return r.listeners(n).length?r.emit(n,t,e):(o[n]||(o[n]=[]),void o[n].push(t))}var r=n("ee").create(),o={};t.exports=e,e.ee=r,r.q=o},{ee:"QJf3ax"}],handle:[function(n,t){t.exports=n("D5DuLP")},{}],XL7HBI:[function(n,t){function e(n){var t=typeof n;return!n||"object"!==t&&"function"!==t?-1:n===window?0:i(n,o,function(){return r++})}var r=1,o="nr@id",i=n("gos");t.exports=e},{gos:"7eSDFh"}],id:[function(n,t){t.exports=n("XL7HBI")},{}],loader:[function(n,t){t.exports=n("G9z0Bl")},{}],G9z0Bl:[function(n,t){function e(){var n=v.info=NREUM.info;if(n&&n.licenseKey&&n.applicationID&&f&&f.body){c(d,function(t,e){t in n||(n[t]=e)}),v.proto="https"===l.split(":")[0]||n.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var t=f.createElement("script");t.src=v.proto+n.agent,f.body.appendChild(t)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=n("handle"),c=n(1),u=window,f=u.document,s="addEventListener",p="attachEvent",l=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-515.min.js"},v=t.exports={offset:i(),origin:l,features:{}};f[s]?(f[s]("DOMContentLoaded",o,!1),u[s]("load",e,!1)):(f[p]("onreadystatechange",r),u[p]("onload",e)),a("mark",["firstbyte",i()])},{1:11,handle:"D5DuLP"}],11:[function(n,t){function e(n,t){var e=[],o="",i=0;for(o in n)r.call(n,o)&&(e[i]=t(o,n[o]),i+=1);return e}var r=Object.prototype.hasOwnProperty;t.exports=e},{}]},{},["G9z0Bl"]);</script>
<meta content='ycLJxifWV5TMCaeBV4zy1XzXAlxSn13YlTqZjZ4_GeQ' name='google-site-verification'>
<!-- / OG and Twitter Card meta data tags -->
<meta content="Clinical Trials for Lung Cancer" property="og:description" />
<meta content="Clinical Trials for Lung Cancer" property="twitter:description" />
<meta content="Clinical Trials for Lung Cancer" property="og:title" />
<meta content="Clinical Trials for Lung Cancer" property="twitter:title" />
<meta content="https://www.smartpatients.com/lung-cancer/trials" property="og:url" />
<meta content="https://www.smartpatients.com/lung-cancer/trials" property="twitter:url" />
<meta content="article" property="og:type" />
<meta content="article" property="twitter:type" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="og:image" />
<meta content="summary" property="twitter:card" />
<meta content="@smart_patients" property="twitter:site" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="twitter:image" />
<script>window.gon = {};gon.browser={"os":null,"platform":null,"browser":"SiteSucker","version":""};gon.selection=null;gon.privileges=[];</script>
<meta content="authenticity_token" name="csrf-param" />
<meta content="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" name="csrf-token" />
<title>Clinical Trials for Lung Cancer | Smart Patients</title>
<!--[if lt IE 10]>
<script src='https://html5shim.googlecode.com/svn/trunk/html5.js'></script>
<![endif]-->
<link href="../assets/application-d023587940a25f1311fac7be224dde01.css" media="all" rel="stylesheet" type="text/css" />
<link href="../assets/print/print-791dc2f04757964770191d5c923539c6.css" media="print" rel="stylesheet" type="text/css" />

<!--[if lt IE 10]>
<link href="/assets/ie/ie-fb3a9d11af866d1ad554b557627df8f6.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<!--[if lt IE 9]>
<link href="/assets/ie/ie8-b1f4d1991397313b50b84b7d76d6ba05.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="https://fonts.googleapis.com/css?family=Handlee%7CBitter:400,700" rel="stylesheet" type="text/css" />

</head>

<body class='not-logged-in'>
<script id='tag_template' type='text/x-handlebars-template'>
<p>
{{{description}}}
</p>
<p class='status_{{tag_name}}'></p>
<p class='tag_link'>
<img alt="Icon_favorite_selected" src="/assets/icon_favorite_selected-37a484115fc7df83408fabd97664140b.png" />
{{{follow_link}}}
</p>
<img alt="Spinner" class="spinner hidden" src="/assets/spinner-3f3b3866a7fa212b261a33db16ecbaf5.gif" />
<div class='topic-count'>
<a href='{{tag_path}}'>
{{{count}}}
</a>
</div>
</script>

<script id='interest_template' type='text/x-handlebars-template'>
<li class='interest' data-interest-id='{{id}}'>
<div class='outer'>
<div class='inner'>
{{{url}}}
{{{remove_link}}}
</div>
</div>
</li>
</script>

<script id='alert_template' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{message}}
</p>
</div>
</script>

<script id='alert_template_html' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{{message}}}
</p>
</div>
</script>

<script id='profile_popup_template' type='text/x-handlebars-template'><pre class='profile_popup'>{{ profile }}</pre><div class='instructions'>
{{ instructions }}
</div>
</script>

<script id='survey_rating_results_template' type='text/x-handlebars-template'>
<div class='rating-result'>
<div>
{{message}}
</div>
<div>
Your rating: {{user_rating}}
</div>
<div>
Average: {{average}}
</div>
<div>
Total # of votes: {{count}}
</div>
</div>
</script>

<script id='target_details_template' type='text/x-handlebars-template'>
<p>
{{name}} <span class="pill {{node_type}}">{{node_type}}</span>
<ul>
{{#each neighbors}}
<li>
{{this.name}} <span class="pill {{this.node_type}}">{{this.node_type}}</span>
</li>
{{/each}}
</ul>
</p>
</script>

<script id='trial_contact_message' type='text/x-handlebars-template'>
I'm interested in "{{{brief_title}}}"
Trial ID: {{trial_id}}
{{institution}}
{{address}}
Thank you in advance for contacting me to discuss this trial.
</script>

<script id='featured_quote_template' type='text/x-handlebars-template'>
<div class='testimonial quoted-snippet'>
{{trimString quote 250}}
</div>
{{#if attribution}}
<div class='signed'>
– {{attribution}}
</div>
{{/if}}
</script>


<div class='container'>
<div class='navbar'>
<div class='navbar-inner'>
<div class='clearfix'>
<div class='row'>
<a href="../index.html" class="brand"><img alt="Smart-patients-logo-350" height="69" src="../assets/smart-patients-logo-350-bb0285894b87daf2798d6c0a81d0c51b.png" style="height: 69px" width="350" /></a>
<ul class='nav'>
</ul>

</div>
</div>
</div>
</div>
</div>

<div class='container' data-title='Clinical Trials for Lung Cancer | Smart Patients' id='page'>
<div class='row'>
<div class='span2'></div>
<div class='span10 divider main'>
<div class='row'>
<div class='span7 messages'>

</div>
</div>
</div>
</div>
<div class='row'>
<div class='span12 divider main'>
<div class='row'>
<div class='span9 right-divider'>

<script id='trial_popover_template' type='text/x-handlebars-template'>
<ul>
{{ds}}
{{#each trials}}
<li>
{{#if this.link}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='{{this.link}}' target='_blank'>
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{else}}
{{#if ../../source}}
<a href='/clinical-trials/{{this.id}}?source={{../../source}}' target='_blank'></a>
{{else}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='/clinical-trials/{{this.id}}' target='_blank'>
{{/if}}
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{/if}}
<p>
{{trimString this.title 120}}
</p>
</li>
{{/each}}
</ul>
</script>




<div id='content-page'>
<div class='content-title'>
<h1>Clinical Trials for Lung Cancer</h1>
</div>
<div class='content-main'>
<p>
Researchers around the world are working to develop new drugs for the treatment of lung cancer. These new treatments must go through a rigorous trial process, testing their safety and efficacy, before they are made available to the people who need them. Patients play a critical role in the development of new treatments through their participation in these clinical trials.
</p>
<p>
New insights into the molecular actions driving cancer have led to new treatments referred to as targeted therapies, because they more precisely identify and attack cancer cells. Below are ongoing clinical trials for lung cancer, including targeted therapies.
</p>
<div class="selector"><span class="selected" data-condition-name="Non-Small Cell Lung Cancer" data-name="non-small-cell-lung-cancer">Non-Small Cell Lung Cancer</span> | <span class="unselected" data-condition-name="Small Cell Lung Cancer" data-name="small-cell-lung-cancer">Small Cell Lung Cancer</span></div><div class="trial-container"><div class="trial_table non-small-cell-lung-cancer_table"><table class='non-small-cell-lung-cancer-nsclc' data-condition-name='Non-Small Cell Lung Cancer' id='trial-widget'>
<tr>
<th>
<div class='condition_name'>
Non-Small Cell Lung Cancer
</div>
</th>
<th>
<div class='big'>
172
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
459
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
131
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
79
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
841
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">Targeted Therapies</td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="BCL2" data-id="non-small-cell-lung-cancer-nsclc" data-name="bcl2_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BCL2</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BCL2" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCL2" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BCL2" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BCL2" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCL2" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="bcl2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Antroquinonol</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="BCR-ABL" data-id="non-small-cell-lung-cancer-nsclc" data-name="bcr-abl_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BCR-ABL</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="bcr-abl_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dasatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Dasatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Dasatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dasatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dasatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dasatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="bcr-abl_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ponatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="EGFR" data-id="non-small-cell-lung-cancer-nsclc" data-name="egfr_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">EGFR</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02228369&quot;,&quot;title&quot;:&quot;An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, AZD3759, in Patients Who Have Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02113813&quot;,&quot;title&quot;:&quot;A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02157883&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02163733&quot;,&quot;title&quot;:&quot;Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197234&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197247&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01918761&quot;,&quot;title&quot;:&quot;Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01967095&quot;,&quot;title&quot;:&quot;Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02080078&quot;,&quot;title&quot;:&quot;A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02134886&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00497250&quot;,&quot;title&quot;:&quot;Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01588145&quot;,&quot;title&quot;:&quot;Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in Non Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02066870&quot;,&quot;title&quot;:&quot;Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00985998&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02083679&quot;,&quot;title&quot;:&quot;Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">28</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01415011&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of BIBW 2992 to Treat Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02192697&quot;,&quot;title&quot;:&quot;An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01802632&quot;,&quot;title&quot;:&quot;AZD9291 First Time In Patients Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094261&quot;,&quot;title&quot;:&quot;Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01102231&quot;,&quot;title&quot;:&quot;Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00561054&quot;,&quot;title&quot;:&quot;Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00985855&quot;,&quot;title&quot;:&quot;Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01059188&quot;,&quot;title&quot;:&quot;Cetuximab, Cisplatin, Docetaxel, Radiation Therapy, and Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01526928&quot;,&quot;title&quot;:&quot;Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02147990&quot;,&quot;title&quot;:&quot;Open Label Safety and Efficacy Study of CO-1686 in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01858389&quot;,&quot;title&quot;:&quot;A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01465802&quot;,&quot;title&quot;:&quot;Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00452075&quot;,&quot;title&quot;:&quot;Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00950365&quot;,&quot;title&quot;:&quot;Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00678964&quot;,&quot;title&quot;:&quot;Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00835471&quot;,&quot;title&quot;:&quot;2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00908336&quot;,&quot;title&quot;:&quot;Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01578668&quot;,&quot;title&quot;:&quot;Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02146118&quot;,&quot;title&quot;:&quot;A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00888511&quot;,&quot;title&quot;:&quot;Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00973310&quot;,&quot;title&quot;:&quot;Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00466284&quot;,&quot;title&quot;:&quot;Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01839955&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00339586&quot;,&quot;title&quot;:&quot;First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00547105&quot;,&quot;title&quot;:&quot;Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00620269&quot;,&quot;title&quot;:&quot;Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01091376&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01131429&quot;,&quot;title&quot;:&quot;A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217619&quot;,&quot;title&quot;:&quot;Erlotinib as Neoadjuvant Treatment in Patients With Stage \u2162A N2 NSCLC With Activating EGFR Mutation.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01410214&quot;,&quot;title&quot;:&quot;Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01470716&quot;,&quot;title&quot;:&quot;Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01683175&quot;,&quot;title&quot;:&quot;Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01714908&quot;,&quot;title&quot;:&quot;Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763385&quot;,&quot;title&quot;:&quot;Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01796288&quot;,&quot;title&quot;:&quot;The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01857271&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02036359&quot;,&quot;title&quot;:&quot;Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02037997&quot;,&quot;title&quot;:&quot;Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02064491&quot;,&quot;title&quot;:&quot;Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02098954&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391260&quot;,&quot;title&quot;:&quot;Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01502202&quot;,&quot;title&quot;:&quot;Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00809237&quot;,&quot;title&quot;:&quot;Hydroxychloroquine and Gefitinib to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01024712&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01192243&quot;,&quot;title&quot;:&quot;Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616499&quot;,&quot;title&quot;:&quot;Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951469&quot;,&quot;title&quot;:&quot;Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01312337&quot;,&quot;title&quot;:&quot;Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01405846&quot;,&quot;title&quot;:&quot;Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01485809&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01510990&quot;,&quot;title&quot;:&quot;First Line Gefitinib by FDG-PET Metabolic Response&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746277&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01749072&quot;,&quot;title&quot;:&quot;Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01755923&quot;,&quot;title&quot;:&quot;Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783834&quot;,&quot;title&quot;:&quot;Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833572&quot;,&quot;title&quot;:&quot;Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01933347&quot;,&quot;title&quot;:&quot;Third-line Treatment of Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025218&quot;,&quot;title&quot;:&quot;Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864681&quot;,&quot;title&quot;:&quot;Combination of Metformin With Gefitinib to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02062515&quot;,&quot;title&quot;:&quot;Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01690390&quot;,&quot;title&quot;:&quot;Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01688713&quot;,&quot;title&quot;:&quot;Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01707329&quot;,&quot;title&quot;:&quot;Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01744925&quot;,&quot;title&quot;:&quot;Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01843647&quot;,&quot;title&quot;:&quot;Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01929200&quot;,&quot;title&quot;:&quot;Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01963195&quot;,&quot;title&quot;:&quot;Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009605&quot;,&quot;title&quot;:&quot;Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02191059&quot;,&quot;title&quot;:&quot;Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763788&quot;,&quot;title&quot;:&quot;A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00983047&quot;,&quot;title&quot;:&quot;Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00979212&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819428&quot;,&quot;title&quot;:&quot;NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">116</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044380&quot;,&quot;title&quot;:&quot;Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01853826&quot;,&quot;title&quot;:&quot;An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01953913&quot;,&quot;title&quot;:&quot;Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02151981&quot;,&quot;title&quot;:&quot;AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887795&quot;,&quot;title&quot;:&quot;Phase \u2162 Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as \ufb01rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00268684&quot;,&quot;title&quot;:&quot;Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00637910&quot;,&quot;title&quot;:&quot;Tarceva Italian Lung Optimization tRial&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00989690&quot;,&quot;title&quot;:&quot;Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01342965&quot;,&quot;title&quot;:&quot;A Study of Tarceva (Erlotinib) Versus Gemcitabine/Cisplatin as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01407822&quot;,&quot;title&quot;:&quot;Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02001896&quot;,&quot;title&quot;:&quot;Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02140333&quot;,&quot;title&quot;:&quot;Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02193282&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01404260&quot;,&quot;title&quot;:&quot;Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01405079&quot;,&quot;title&quot;:&quot;Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01719536&quot;,&quot;title&quot;:&quot;Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01724801&quot;,&quot;title&quot;:&quot;Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01996098&quot;,&quot;title&quot;:&quot;Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125240&quot;,&quot;title&quot;:&quot;Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">29</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00903292&quot;,&quot;title&quot;:&quot;Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01320501&quot;,&quot;title&quot;:&quot;Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02000531&quot;,&quot;title&quot;:&quot;A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01665417&quot;,&quot;title&quot;:&quot;Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01646450&quot;,&quot;title&quot;:&quot;First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01926171&quot;,&quot;title&quot;:&quot;Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01393080&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">11</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00903292&quot;,&quot;title&quot;:&quot;Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01320501&quot;,&quot;title&quot;:&quot;Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02000531&quot;,&quot;title&quot;:&quot;A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01665417&quot;,&quot;title&quot;:&quot;Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01646450&quot;,&quot;title&quot;:&quot;First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01926171&quot;,&quot;title&quot;:&quot;Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01393080&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02228369&quot;,&quot;title&quot;:&quot;An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, AZD3759, in Patients Who Have Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02113813&quot;,&quot;title&quot;:&quot;A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02157883&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02163733&quot;,&quot;title&quot;:&quot;Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197234&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197247&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01918761&quot;,&quot;title&quot;:&quot;Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01967095&quot;,&quot;title&quot;:&quot;Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02080078&quot;,&quot;title&quot;:&quot;A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02134886&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00497250&quot;,&quot;title&quot;:&quot;Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01588145&quot;,&quot;title&quot;:&quot;Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in Non Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02066870&quot;,&quot;title&quot;:&quot;Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00985998&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02083679&quot;,&quot;title&quot;:&quot;Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01415011&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of BIBW 2992 to Treat Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02192697&quot;,&quot;title&quot;:&quot;An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01802632&quot;,&quot;title&quot;:&quot;AZD9291 First Time In Patients Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094261&quot;,&quot;title&quot;:&quot;Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01102231&quot;,&quot;title&quot;:&quot;Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00561054&quot;,&quot;title&quot;:&quot;Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00985855&quot;,&quot;title&quot;:&quot;Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01059188&quot;,&quot;title&quot;:&quot;Cetuximab, Cisplatin, Docetaxel, Radiation Therapy, and Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01526928&quot;,&quot;title&quot;:&quot;Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02147990&quot;,&quot;title&quot;:&quot;Open Label Safety and Efficacy Study of CO-1686 in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01858389&quot;,&quot;title&quot;:&quot;A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01465802&quot;,&quot;title&quot;:&quot;Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00452075&quot;,&quot;title&quot;:&quot;Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00950365&quot;,&quot;title&quot;:&quot;Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00678964&quot;,&quot;title&quot;:&quot;Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00835471&quot;,&quot;title&quot;:&quot;2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00908336&quot;,&quot;title&quot;:&quot;Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01578668&quot;,&quot;title&quot;:&quot;Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02146118&quot;,&quot;title&quot;:&quot;A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00888511&quot;,&quot;title&quot;:&quot;Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00973310&quot;,&quot;title&quot;:&quot;Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00466284&quot;,&quot;title&quot;:&quot;Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01839955&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00339586&quot;,&quot;title&quot;:&quot;First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00547105&quot;,&quot;title&quot;:&quot;Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00620269&quot;,&quot;title&quot;:&quot;Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01091376&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01131429&quot;,&quot;title&quot;:&quot;A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217619&quot;,&quot;title&quot;:&quot;Erlotinib as Neoadjuvant Treatment in Patients With Stage \u2162A N2 NSCLC With Activating EGFR Mutation.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01410214&quot;,&quot;title&quot;:&quot;Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01470716&quot;,&quot;title&quot;:&quot;Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01683175&quot;,&quot;title&quot;:&quot;Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01714908&quot;,&quot;title&quot;:&quot;Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763385&quot;,&quot;title&quot;:&quot;Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01796288&quot;,&quot;title&quot;:&quot;The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01857271&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02036359&quot;,&quot;title&quot;:&quot;Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02037997&quot;,&quot;title&quot;:&quot;Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02064491&quot;,&quot;title&quot;:&quot;Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02098954&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391260&quot;,&quot;title&quot;:&quot;Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01502202&quot;,&quot;title&quot;:&quot;Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00809237&quot;,&quot;title&quot;:&quot;Hydroxychloroquine and Gefitinib to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01024712&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01192243&quot;,&quot;title&quot;:&quot;Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616499&quot;,&quot;title&quot;:&quot;Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951469&quot;,&quot;title&quot;:&quot;Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01312337&quot;,&quot;title&quot;:&quot;Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01405846&quot;,&quot;title&quot;:&quot;Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01485809&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01510990&quot;,&quot;title&quot;:&quot;First Line Gefitinib by FDG-PET Metabolic Response&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746277&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01749072&quot;,&quot;title&quot;:&quot;Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01755923&quot;,&quot;title&quot;:&quot;Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783834&quot;,&quot;title&quot;:&quot;Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833572&quot;,&quot;title&quot;:&quot;Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01933347&quot;,&quot;title&quot;:&quot;Third-line Treatment of Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025218&quot;,&quot;title&quot;:&quot;Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864681&quot;,&quot;title&quot;:&quot;Combination of Metformin With Gefitinib to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02062515&quot;,&quot;title&quot;:&quot;Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01690390&quot;,&quot;title&quot;:&quot;Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01688713&quot;,&quot;title&quot;:&quot;Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01707329&quot;,&quot;title&quot;:&quot;Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01744925&quot;,&quot;title&quot;:&quot;Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01843647&quot;,&quot;title&quot;:&quot;Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01929200&quot;,&quot;title&quot;:&quot;Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01963195&quot;,&quot;title&quot;:&quot;Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009605&quot;,&quot;title&quot;:&quot;Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02191059&quot;,&quot;title&quot;:&quot;Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763788&quot;,&quot;title&quot;:&quot;A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00983047&quot;,&quot;title&quot;:&quot;Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00979212&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819428&quot;,&quot;title&quot;:&quot;NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02044380&quot;,&quot;title&quot;:&quot;Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01853826&quot;,&quot;title&quot;:&quot;An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01953913&quot;,&quot;title&quot;:&quot;Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02151981&quot;,&quot;title&quot;:&quot;AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887795&quot;,&quot;title&quot;:&quot;Phase \u2162 Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as \ufb01rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00268684&quot;,&quot;title&quot;:&quot;Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00637910&quot;,&quot;title&quot;:&quot;Tarceva Italian Lung Optimization tRial&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00989690&quot;,&quot;title&quot;:&quot;Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01342965&quot;,&quot;title&quot;:&quot;A Study of Tarceva (Erlotinib) Versus Gemcitabine/Cisplatin as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01407822&quot;,&quot;title&quot;:&quot;Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02001896&quot;,&quot;title&quot;:&quot;Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02140333&quot;,&quot;title&quot;:&quot;Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02193282&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01404260&quot;,&quot;title&quot;:&quot;Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01405079&quot;,&quot;title&quot;:&quot;Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01719536&quot;,&quot;title&quot;:&quot;Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01724801&quot;,&quot;title&quot;:&quot;Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01996098&quot;,&quot;title&quot;:&quot;Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125240&quot;,&quot;title&quot;:&quot;Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">184</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Afatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999985&quot;,&quot;title&quot;:&quot;Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01415011&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of BIBW 2992 to Treat Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044380&quot;,&quot;title&quot;:&quot;Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01853826&quot;,&quot;title&quot;:&quot;An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01953913&quot;,&quot;title&quot;:&quot;Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">17</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD3759</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD3759" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02228369&quot;,&quot;title&quot;:&quot;An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, AZD3759, in Patients Who Have Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD3759" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD3759" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD3759" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD3759" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ASP8273</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="ASP8273" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02113813&quot;,&quot;title&quot;:&quot;A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ASP8273" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02192697&quot;,&quot;title&quot;:&quot;An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="ASP8273" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ASP8273" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ASP8273" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD8931</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD9291</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD9291" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02157883&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02163733&quot;,&quot;title&quot;:&quot;Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197234&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02197247&quot;,&quot;title&quot;:&quot;Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD9291" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01802632&quot;,&quot;title&quot;:&quot;AZD9291 First Time In Patients Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094261&quot;,&quot;title&quot;:&quot;Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD9291" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02151981&quot;,&quot;title&quot;:&quot;AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD9291" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD9291" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">8</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cetuximab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cetuximab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cetuximab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01102231&quot;,&quot;title&quot;:&quot;Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00561054&quot;,&quot;title&quot;:&quot;Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00985855&quot;,&quot;title&quot;:&quot;Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01059188&quot;,&quot;title&quot;:&quot;Cetuximab, Cisplatin, Docetaxel, Radiation Therapy, and Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cetuximab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cetuximab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cetuximab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CO-1686</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="CO-1686" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CO-1686" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01526928&quot;,&quot;title&quot;:&quot;Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02147990&quot;,&quot;title&quot;:&quot;Open Label Safety and Efficacy Study of CO-1686 in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="CO-1686" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CO-1686" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CO-1686" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dacomitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Dacomitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01918761&quot;,&quot;title&quot;:&quot;Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dacomitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01858389&quot;,&quot;title&quot;:&quot;A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01465802&quot;,&quot;title&quot;:&quot;Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dacomitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Dacomitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dacomitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Erlotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01967095&quot;,&quot;title&quot;:&quot;Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02080078&quot;,&quot;title&quot;:&quot;A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02134886&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">9</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00452075&quot;,&quot;title&quot;:&quot;Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00950365&quot;,&quot;title&quot;:&quot;Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00678964&quot;,&quot;title&quot;:&quot;Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00835471&quot;,&quot;title&quot;:&quot;2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00908336&quot;,&quot;title&quot;:&quot;Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01578668&quot;,&quot;title&quot;:&quot;Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02146118&quot;,&quot;title&quot;:&quot;A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00888511&quot;,&quot;title&quot;:&quot;Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00973310&quot;,&quot;title&quot;:&quot;Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00466284&quot;,&quot;title&quot;:&quot;Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01839955&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00339586&quot;,&quot;title&quot;:&quot;First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00547105&quot;,&quot;title&quot;:&quot;Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00620269&quot;,&quot;title&quot;:&quot;Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01091376&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01131429&quot;,&quot;title&quot;:&quot;A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217619&quot;,&quot;title&quot;:&quot;Erlotinib as Neoadjuvant Treatment in Patients With Stage \u2162A N2 NSCLC With Activating EGFR Mutation.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01410214&quot;,&quot;title&quot;:&quot;Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01470716&quot;,&quot;title&quot;:&quot;Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01683175&quot;,&quot;title&quot;:&quot;Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01714908&quot;,&quot;title&quot;:&quot;Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763385&quot;,&quot;title&quot;:&quot;Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01796288&quot;,&quot;title&quot;:&quot;The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01857271&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02036359&quot;,&quot;title&quot;:&quot;Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02037997&quot;,&quot;title&quot;:&quot;Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02064491&quot;,&quot;title&quot;:&quot;Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02098954&quot;,&quot;title&quot;:&quot;Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186301&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">48</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01887795&quot;,&quot;title&quot;:&quot;Phase \u2162 Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as \ufb01rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00268684&quot;,&quot;title&quot;:&quot;Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00637910&quot;,&quot;title&quot;:&quot;Tarceva Italian Lung Optimization tRial&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00989690&quot;,&quot;title&quot;:&quot;Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01342965&quot;,&quot;title&quot;:&quot;A Study of Tarceva (Erlotinib) Versus Gemcitabine/Cisplatin as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01407822&quot;,&quot;title&quot;:&quot;Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02001896&quot;,&quot;title&quot;:&quot;Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02140333&quot;,&quot;title&quot;:&quot;Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02193282&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">15</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00903292&quot;,&quot;title&quot;:&quot;Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01320501&quot;,&quot;title&quot;:&quot;Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02000531&quot;,&quot;title&quot;:&quot;A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;}]">4</td><td data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">76</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Gefitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Gefitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00497250&quot;,&quot;title&quot;:&quot;Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gefitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391260&quot;,&quot;title&quot;:&quot;Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01502202&quot;,&quot;title&quot;:&quot;Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00809237&quot;,&quot;title&quot;:&quot;Hydroxychloroquine and Gefitinib to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01024712&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01192243&quot;,&quot;title&quot;:&quot;Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616499&quot;,&quot;title&quot;:&quot;Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951469&quot;,&quot;title&quot;:&quot;Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01312337&quot;,&quot;title&quot;:&quot;Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01405846&quot;,&quot;title&quot;:&quot;Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01485809&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01510990&quot;,&quot;title&quot;:&quot;First Line Gefitinib by FDG-PET Metabolic Response&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746277&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01749072&quot;,&quot;title&quot;:&quot;Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01755923&quot;,&quot;title&quot;:&quot;Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783834&quot;,&quot;title&quot;:&quot;Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833572&quot;,&quot;title&quot;:&quot;Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928160&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01933347&quot;,&quot;title&quot;:&quot;Third-line Treatment of Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01955421&quot;,&quot;title&quot;:&quot;Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025218&quot;,&quot;title&quot;:&quot;Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864681&quot;,&quot;title&quot;:&quot;Combination of Metformin With Gefitinib to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">28</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gefitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01404260&quot;,&quot;title&quot;:&quot;Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01405079&quot;,&quot;title&quot;:&quot;Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774721&quot;,&quot;title&quot;:&quot;ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gefitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01776684&quot;,&quot;title&quot;:&quot;Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Gefitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">37</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">HM61713</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HM61713" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588145&quot;,&quot;title&quot;:&quot;Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in Non Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="HM61713" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HM61713" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HM61713" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HM61713" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Icotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Icotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02066870&quot;,&quot;title&quot;:&quot;Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Icotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02062515&quot;,&quot;title&quot;:&quot;Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01690390&quot;,&quot;title&quot;:&quot;Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01688713&quot;,&quot;title&quot;:&quot;Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01707329&quot;,&quot;title&quot;:&quot;Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01744925&quot;,&quot;title&quot;:&quot;Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01843647&quot;,&quot;title&quot;:&quot;Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01929200&quot;,&quot;title&quot;:&quot;Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01963195&quot;,&quot;title&quot;:&quot;Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009605&quot;,&quot;title&quot;:&quot;Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02191059&quot;,&quot;title&quot;:&quot;Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">10</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Icotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01719536&quot;,&quot;title&quot;:&quot;Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01724801&quot;,&quot;title&quot;:&quot;Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01996098&quot;,&quot;title&quot;:&quot;Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125240&quot;,&quot;title&quot;:&quot;Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Icotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01665417&quot;,&quot;title&quot;:&quot;Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01646450&quot;,&quot;title&quot;:&quot;First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01926171&quot;,&quot;title&quot;:&quot;Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;other&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Icotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">18</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lapatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Necitumumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Necitumumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Necitumumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01763788&quot;,&quot;title&quot;:&quot;A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Necitumumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Necitumumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Necitumumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nimotuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Nimotuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00985998&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nimotuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00983047&quot;,&quot;title&quot;:&quot;Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498562&quot;,&quot;title&quot;:&quot;Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Nimotuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nimotuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01393080&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Nimotuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Panitumumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Panitumumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Panitumumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00979212&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Panitumumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Panitumumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Panitumumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Poziotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Poziotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Poziotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01819428&quot;,&quot;title&quot;:&quot;NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Poziotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Poziotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Poziotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sym004</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Sym004" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02083679&quot;,&quot;title&quot;:&quot;Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Sym004" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sym004" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sym004" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sym004" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="RAS" data-id="non-small-cell-lung-cancer-nsclc" data-name="ras_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">RAS</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="RAS" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="RAS" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833143&quot;,&quot;title&quot;:&quot;Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="RAS" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RAS" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="RAS" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833143&quot;,&quot;title&quot;:&quot;Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class="ras_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Antroquinonol</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02047344&quot;,&quot;title&quot;:&quot;Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Antroquinonol" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ras_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bortezomib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01833143&quot;,&quot;title&quot;:&quot;Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ras_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Selumetinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="BRAF" data-id="non-small-cell-lung-cancer-nsclc" data-name="braf_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BRAF</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BRAF" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BRAF" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BRAF" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BRAF" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BRAF" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="braf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dabrafenib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Dabrafenib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dabrafenib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Dabrafenib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dabrafenib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dabrafenib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="MEK" data-id="non-small-cell-lung-cancer-nsclc" data-name="mek_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEK</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01859026&quot;,&quot;title&quot;:&quot;A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02185690&quot;,&quot;title&quot;:&quot;A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01783197&quot;,&quot;title&quot;:&quot;Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01809210&quot;,&quot;title&quot;:&quot;Assess Safety \u0026 Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01146756&quot;,&quot;title&quot;:&quot;MEK Inhibitor and Thoracic Radiotherapy Trial&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01938456&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01912625&quot;,&quot;title&quot;:&quot;Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">11</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01750281&quot;,&quot;title&quot;:&quot;Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">10</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01933932&quot;,&quot;title&quot;:&quot;Assess Efficacy \u0026 Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MEK" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01859026&quot;,&quot;title&quot;:&quot;A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02185690&quot;,&quot;title&quot;:&quot;A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01783197&quot;,&quot;title&quot;:&quot;Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01809210&quot;,&quot;title&quot;:&quot;Assess Safety \u0026 Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01146756&quot;,&quot;title&quot;:&quot;MEK Inhibitor and Thoracic Radiotherapy Trial&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01938456&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01912625&quot;,&quot;title&quot;:&quot;Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01750281&quot;,&quot;title&quot;:&quot;Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01933932&quot;,&quot;title&quot;:&quot;Assess Efficacy \u0026 Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">22</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD6244</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GSK1120212</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK1120212" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GSK1120212" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK1120212" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK1120212" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK1120212" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEK162</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK162" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01859026&quot;,&quot;title&quot;:&quot;A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02185690&quot;,&quot;title&quot;:&quot;A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="MEK162" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MEK162" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MEK162" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MEK162" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PD-0325901</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="PD-0325901" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PD-0325901" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039336&quot;,&quot;title&quot;:&quot;Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="PD-0325901" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PD-0325901" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PD-0325901" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Selumetinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01783197&quot;,&quot;title&quot;:&quot;Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01809210&quot;,&quot;title&quot;:&quot;Assess Safety \u0026 Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01146756&quot;,&quot;title&quot;:&quot;MEK Inhibitor and Thoracic Radiotherapy Trial&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02025114&quot;,&quot;title&quot;:&quot;Selumetinib in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01750281&quot;,&quot;title&quot;:&quot;Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01933932&quot;,&quot;title&quot;:&quot;Assess Efficacy \u0026 Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Selumetinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">9</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Trametinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Trametinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01938456&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01912625&quot;,&quot;title&quot;:&quot;Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Trametinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336634&quot;,&quot;title&quot;:&quot;Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Trametinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Trametinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Trametinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PI3K (PI3K/AKT)" data-id="non-small-cell-lung-cancer-nsclc" data-name="pi3k-pi3k-akt_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PI3K (PI3K/AKT)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01884285&quot;,&quot;title&quot;:&quot;AZD8186 First Time In Patient Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01723800&quot;,&quot;title&quot;:&quot;PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02128724&quot;,&quot;title&quot;:&quot;Palliative Thoracic Radiotherapy Plus BKM120&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00776867&quot;,&quot;title&quot;:&quot;Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">6</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01911325&quot;,&quot;title&quot;:&quot;Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01820325&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01902173&quot;,&quot;title&quot;:&quot;GSK2141795 and Dabrafenib in Treating Patients With Stage IIIC-IV Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01884285&quot;,&quot;title&quot;:&quot;AZD8186 First Time In Patient Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01723800&quot;,&quot;title&quot;:&quot;PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02128724&quot;,&quot;title&quot;:&quot;Palliative Thoracic Radiotherapy Plus BKM120&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00776867&quot;,&quot;title&quot;:&quot;Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01911325&quot;,&quot;title&quot;:&quot;Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01820325&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01902173&quot;,&quot;title&quot;:&quot;GSK2141795 and Dabrafenib in Treating Patients With Stage IIIC-IV Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">15</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD5363</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD8186</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD8186" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01884285&quot;,&quot;title&quot;:&quot;AZD8186 First Time In Patient Ascending Dose Study&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD8186" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8186" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8186" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8186" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Buparlisib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01570296&quot;,&quot;title&quot;:&quot;A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01723800&quot;,&quot;title&quot;:&quot;PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02128724&quot;,&quot;title&quot;:&quot;Palliative Thoracic Radiotherapy Plus BKM120&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01911325&quot;,&quot;title&quot;:&quot;Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01820325&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01487265&quot;,&quot;title&quot;:&quot;Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">6</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cixutumumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cixutumumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cixutumumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cixutumumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cixutumumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cixutumumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GDC-0032</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="GDC-0032" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GDC-0032" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GDC-0032" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GDC-0032" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GDC-0032" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GDC-0941</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="GDC-0941" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GDC-0941" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GDC-0941" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GDC-0941" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GDC-0941" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GSK2141795</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK2141795" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01138085&quot;,&quot;title&quot;:&quot;Safety, Pharmacokinetics (PK) of AKT and MEK Combination&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK2141795" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01902173&quot;,&quot;title&quot;:&quot;GSK2141795 and Dabrafenib in Treating Patients With Stage IIIC-IV Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GSK2141795" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK2141795" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK2141795" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MK-2206</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Perifosine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Perifosine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00776867&quot;,&quot;title&quot;:&quot;Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Perifosine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Perifosine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Perifosine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Perifosine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="ALK and EML4-ALK" data-id="non-small-cell-lung-cancer-nsclc" data-name="alk-and-eml4-alk_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ALK and EML4-ALK</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="ALK and EML4-ALK" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01548144&quot;,&quot;title&quot;:&quot;Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625234&quot;,&quot;title&quot;:&quot;Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">6</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ALK and EML4-ALK" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01449461&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094573&quot;,&quot;title&quot;:&quot;A Phase 2, Multicenter, Randomized Study of AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183870&quot;,&quot;title&quot;:&quot;EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134912&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02040870&quot;,&quot;title&quot;:&quot;LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00932451&quot;,&quot;title&quot;:&quot;An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871805&quot;,&quot;title&quot;:&quot;A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">14</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ALK and EML4-ALK" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01639001&quot;,&quot;title&quot;:&quot;A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02201992&quot;,&quot;title&quot;:&quot;Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01828099&quot;,&quot;title&quot;:&quot;LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td><td data-content-name="lung-cancer" data-intervention="ALK and EML4-ALK" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ALK and EML4-ALK" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01548144&quot;,&quot;title&quot;:&quot;Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625234&quot;,&quot;title&quot;:&quot;Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01449461&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094573&quot;,&quot;title&quot;:&quot;A Phase 2, Multicenter, Randomized Study of AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183870&quot;,&quot;title&quot;:&quot;EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134912&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02040870&quot;,&quot;title&quot;:&quot;LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00932451&quot;,&quot;title&quot;:&quot;An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871805&quot;,&quot;title&quot;:&quot;A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01639001&quot;,&quot;title&quot;:&quot;A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02201992&quot;,&quot;title&quot;:&quot;Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01828099&quot;,&quot;title&quot;:&quot;LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">25</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alectinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Alectinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Alectinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Alectinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Alectinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Alectinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AP26113</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AP26113" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AP26113" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01449461&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094573&quot;,&quot;title&quot;:&quot;A Phase 2, Multicenter, Randomized Study of AP26113&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="AP26113" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AP26113" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AP26113" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD5363</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD5363" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Crizotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01548144&quot;,&quot;title&quot;:&quot;Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183870&quot;,&quot;title&quot;:&quot;EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134912&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822496&quot;,&quot;title&quot;:&quot;Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02075840&quot;,&quot;title&quot;:&quot;ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01639001&quot;,&quot;title&quot;:&quot;A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02201992&quot;,&quot;title&quot;:&quot;Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">11</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LDK378</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02040870&quot;,&quot;title&quot;:&quot;LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01828099&quot;,&quot;title&quot;:&quot;LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">4</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MK-2206</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PF-02341066</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="PF-02341066" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PF-02341066" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00932451&quot;,&quot;title&quot;:&quot;An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="PF-02341066" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-02341066" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-02341066" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PF-05212384</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">RO5424802</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="RO5424802" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="RO5424802" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01871805&quot;,&quot;title&quot;:&quot;A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="RO5424802" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RO5424802" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RO5424802" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="alk-and-eml4-alk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">X-396</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="X-396" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625234&quot;,&quot;title&quot;:&quot;Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="X-396" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="X-396" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="X-396" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="X-396" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="ROS1" data-id="non-small-cell-lung-cancer-nsclc" data-name="ros1_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ROS1</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="ROS1" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ROS1" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="ROS1" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ROS1" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ROS1" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class="ros1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Crizotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01945021&quot;,&quot;title&quot;:&quot;Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Crizotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ros1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LDK378</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01964157&quot;,&quot;title&quot;:&quot;An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDK378" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ros1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PF-06463922</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="PF-06463922" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PF-06463922" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01970865&quot;,&quot;title&quot;:&quot;A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PF-06463922" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-06463922" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-06463922" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="mTOR" data-id="non-small-cell-lung-cancer-nsclc" data-name="mtor_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">mTOR</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02193633&quot;,&quot;title&quot;:&quot;A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01317615&quot;,&quot;title&quot;:&quot;RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01317615&quot;,&quot;title&quot;:&quot;RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02193633&quot;,&quot;title&quot;:&quot;A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD2014</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD2014" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02193633&quot;,&quot;title&quot;:&quot;A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD2014" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD2014" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD2014" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD2014" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CC-223</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="CC-223" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01545947&quot;,&quot;title&quot;:&quot;Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="CC-223" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CC-223" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CC-223" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CC-223" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Everolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01317615&quot;,&quot;title&quot;:&quot;RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PF-05212384</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02069158&quot;,&quot;title&quot;:&quot;Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PF-05212384" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sirolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Heat Shock Proteins" data-id="non-small-cell-lung-cancer-nsclc" data-name="heat-shock-proteins_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Heat Shock Proteins</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Heat Shock Proteins" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01784640&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714037&quot;,&quot;title&quot;:&quot;A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Heat Shock Proteins" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01646125&quot;,&quot;title&quot;:&quot;An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01752400&quot;,&quot;title&quot;:&quot;AUY922 for Advanced ALK-positive NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01854034&quot;,&quot;title&quot;:&quot;Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01922583&quot;,&quot;title&quot;:&quot;AUY922 in Patient With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01829113&quot;,&quot;title&quot;:&quot;Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848756&quot;,&quot;title&quot;:&quot;Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117024&quot;,&quot;title&quot;:&quot;A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Heat Shock Proteins" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01798485&quot;,&quot;title&quot;:&quot;A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Heat Shock Proteins" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Heat Shock Proteins" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01784640&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714037&quot;,&quot;title&quot;:&quot;A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01646125&quot;,&quot;title&quot;:&quot;An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01752400&quot;,&quot;title&quot;:&quot;AUY922 for Advanced ALK-positive NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01854034&quot;,&quot;title&quot;:&quot;Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01922583&quot;,&quot;title&quot;:&quot;AUY922 in Patient With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01829113&quot;,&quot;title&quot;:&quot;Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848756&quot;,&quot;title&quot;:&quot;Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117024&quot;,&quot;title&quot;:&quot;A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01798485&quot;,&quot;title&quot;:&quot;A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">13</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AT13387</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AT13387" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AT13387" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01712217&quot;,&quot;title&quot;:&quot;A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AT13387" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AT13387" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AT13387" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AUY922</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AUY922" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01772797&quot;,&quot;title&quot;:&quot;Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01784640&quot;,&quot;title&quot;:&quot;Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AUY922" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01646125&quot;,&quot;title&quot;:&quot;An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01752400&quot;,&quot;title&quot;:&quot;AUY922 for Advanced ALK-positive NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01854034&quot;,&quot;title&quot;:&quot;Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01922583&quot;,&quot;title&quot;:&quot;AUY922 in Patient With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td data-content-name="lung-cancer" data-intervention="AUY922" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AUY922" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AUY922" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">6</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">DEBIO-0932</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="DEBIO-0932" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01714037&quot;,&quot;title&quot;:&quot;A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="DEBIO-0932" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DEBIO-0932" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DEBIO-0932" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DEBIO-0932" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ganetespib (STA-9090)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ganetespib (STA-9090)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579994&quot;,&quot;title&quot;:&quot;Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ganetespib (STA-9090)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ganetespib (STA-9090)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01798485&quot;,&quot;title&quot;:&quot;A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ganetespib (STA-9090)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ganetespib (STA-9090)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">OGX-427</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="OGX-427" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="OGX-427" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01829113&quot;,&quot;title&quot;:&quot;Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="OGX-427" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OGX-427" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OGX-427" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">SNX-5422</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="SNX-5422" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="SNX-5422" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01848756&quot;,&quot;title&quot;:&quot;Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="SNX-5422" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="SNX-5422" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="SNX-5422" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Viagenpumatucel-L</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Viagenpumatucel-L" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Viagenpumatucel-L" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117024&quot;,&quot;title&quot;:&quot;A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Viagenpumatucel-L" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Viagenpumatucel-L" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Viagenpumatucel-L" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="HER2" data-id="non-small-cell-lung-cancer-nsclc" data-name="her2_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">HER2</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HER2" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER2" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01827267&quot;,&quot;title&quot;:&quot;Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02226757&quot;,&quot;title&quot;:&quot;Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">11</td><td data-content-name="lung-cancer" data-intervention="HER2" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER2" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER2" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01827267&quot;,&quot;title&quot;:&quot;Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02226757&quot;,&quot;title&quot;:&quot;Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">15</td></div></td></tr><tr class="her2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Afatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01647711&quot;,&quot;title&quot;:&quot;A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01861223&quot;,&quot;title&quot;:&quot;Afatinib Plus Nimotuzumb for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01932229&quot;,&quot;title&quot;:&quot;An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01542437&quot;,&quot;title&quot;:&quot;Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553942&quot;,&quot;title&quot;:&quot;Afatinib With CT and RT for EGFR-Mutant NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01746251&quot;,&quot;title&quot;:&quot;Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02183883&quot;,&quot;title&quot;:&quot;Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">7</td><td data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02208843&quot;,&quot;title&quot;:&quot;Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Afatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">11</td></div></td></tr><tr class="her2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD8931</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="her2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lapatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02230553&quot;,&quot;title&quot;:&quot;Lapatinib Plus Trametinib in KRAS Mutant Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="her2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Neratinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Neratinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Neratinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01827267&quot;,&quot;title&quot;:&quot;Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Neratinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Neratinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Neratinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="her2_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Traztuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Traztuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Traztuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02226757&quot;,&quot;title&quot;:&quot;Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Traztuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Traztuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Traztuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="HER3" data-id="non-small-cell-lung-cancer-nsclc" data-name="her3_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">HER3</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HER3" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02204345&quot;,&quot;title&quot;:&quot;A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER3" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER3" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="HER3" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HER3" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02204345&quot;,&quot;title&quot;:&quot;A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td></div></td></tr><tr class="her3_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD8931</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD8931" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="her3_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Patritumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Patritumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Patritumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Patritumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02134015&quot;,&quot;title&quot;:&quot;Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Patritumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Patritumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="her3_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">RO5479599</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="RO5479599" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02204345&quot;,&quot;title&quot;:&quot;A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="RO5479599" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RO5479599" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RO5479599" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RO5479599" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="c-MET (Met)" data-id="non-small-cell-lung-cancer-nsclc" data-name="c-met-met_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">c-MET (Met)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="c-MET (Met)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01911507&quot;,&quot;title&quot;:&quot;INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02219711&quot;,&quot;title&quot;:&quot;Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="c-MET (Met)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01900652&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01897480&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="c-MET (Met)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="c-MET (Met)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="c-MET (Met)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01911507&quot;,&quot;title&quot;:&quot;INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02219711&quot;,&quot;title&quot;:&quot;Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01900652&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01897480&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">14</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cabozantinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">INC280</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="INC280" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01911507&quot;,&quot;title&quot;:&quot;INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="INC280" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01610336&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="INC280" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="INC280" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="INC280" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LY2875358</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2875358" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01287546&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2875358" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01900652&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01897480&quot;,&quot;title&quot;:&quot;A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="LY2875358" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2875358" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2875358" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MSC2156119J</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MSC2156119J" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MSC2156119J" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01982955&quot;,&quot;title&quot;:&quot;MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MSC2156119J" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MSC2156119J" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MSC2156119J" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MGCD516</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MGCD516" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02219711&quot;,&quot;title&quot;:&quot;Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MGCD516" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGCD516" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGCD516" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGCD516" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MGCD265</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MGCD265" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MGCD265" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00975767&quot;,&quot;title&quot;:&quot;A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MGCD265" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGCD265" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGCD265" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Onartuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Onartuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Onartuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Onartuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01887886&quot;,&quot;title&quot;:&quot;A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02031744&quot;,&quot;title&quot;:&quot;A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Onartuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Onartuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Rilotumumab (AMG 102)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Rilotumumab (AMG 102)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Rilotumumab (AMG 102)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01233687&quot;,&quot;title&quot;:&quot;AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab (AMG 102)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab (AMG 102)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab (AMG 102)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="c-met-met_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Volitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Volitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Volitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Volitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Volitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Volitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="RET" data-id="non-small-cell-lung-cancer-nsclc" data-name="ret_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">RET</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="RET" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="RET" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01639508&quot;,&quot;title&quot;:&quot;Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01877083&quot;,&quot;title&quot;:&quot;Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01813734&quot;,&quot;title&quot;:&quot;Ponatinib in Advanced NSCLC w/ RET Translocations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="RET" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RET" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="RET" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01639508&quot;,&quot;title&quot;:&quot;Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01877083&quot;,&quot;title&quot;:&quot;Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01813734&quot;,&quot;title&quot;:&quot;Ponatinib in Advanced NSCLC w/ RET Translocations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class="ret_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cabozantinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01639508&quot;,&quot;title&quot;:&quot;Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozantinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ret_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lenvatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lenvatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lenvatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01877083&quot;,&quot;title&quot;:&quot;Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lenvatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lenvatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lenvatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="ret_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ponatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01813734&quot;,&quot;title&quot;:&quot;Ponatinib in Advanced NSCLC w/ RET Translocations&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="FGFR" data-id="non-small-cell-lung-cancer-nsclc" data-name="fgfr_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">FGFR</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="FGFR" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01868022&quot;,&quot;title&quot;:&quot;Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="FGFR" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795768&quot;,&quot;title&quot;:&quot;Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01676714&quot;,&quot;title&quot;:&quot;Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861197&quot;,&quot;title&quot;:&quot;Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="lung-cancer" data-intervention="FGFR" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="FGFR" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="FGFR" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01868022&quot;,&quot;title&quot;:&quot;Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01795768&quot;,&quot;title&quot;:&quot;Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01676714&quot;,&quot;title&quot;:&quot;Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861197&quot;,&quot;title&quot;:&quot;Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td></div></td></tr><tr class="fgfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ADZ4547</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="ADZ4547" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ADZ4547" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795768&quot;,&quot;title&quot;:&quot;Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ADZ4547" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="ADZ4547" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ADZ4547" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="fgfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GSK3052230</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK3052230" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01868022&quot;,&quot;title&quot;:&quot;Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GSK3052230" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK3052230" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK3052230" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK3052230" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="fgfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dovitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Dovitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dovitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01676714&quot;,&quot;title&quot;:&quot;Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861197&quot;,&quot;title&quot;:&quot;Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Dovitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dovitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dovitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="fgfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lucitanib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="VEGF" data-id="non-small-cell-lung-cancer-nsclc" data-name="vegf_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VEGF</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01218867&quot;,&quot;title&quot;:&quot;Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054052&quot;,&quot;title&quot;:&quot;Intrapleural Bevacizumab Injection for Malignant Pleural Effusion in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00254319&quot;,&quot;title&quot;:&quot;Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01980472&quot;,&quot;title&quot;:&quot;A Phase II Study of Chemotherapy Regimen Plus Bevacizumab in Elderly Non-small Cell Lung Cancer (NSCLC) Patients Selected by Geriatric Assessment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01588704&quot;,&quot;title&quot;:&quot;Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741221&quot;,&quot;title&quot;:&quot;Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01171170&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00150657&quot;,&quot;title&quot;:&quot;Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01705184&quot;,&quot;title&quot;:&quot;Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741195&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00755170&quot;,&quot;title&quot;:&quot;Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01623102&quot;,&quot;title&quot;:&quot;Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01649947&quot;,&quot;title&quot;:&quot;Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753909&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01770171&quot;,&quot;title&quot;:&quot;Carboplatin-Paclitaxel \u00b1 Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951482&quot;,&quot;title&quot;:&quot;Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005120&quot;,&quot;title&quot;:&quot;Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179567&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200354&quot;,&quot;title&quot;:&quot;The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">29</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01763645&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02162537&quot;,&quot;title&quot;:&quot;Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01763671&quot;,&quot;title&quot;:&quot;Paclitaxel-bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01351415&quot;,&quot;title&quot;:&quot;A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01107626&quot;,&quot;title&quot;:&quot;Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01063283&quot;,&quot;title&quot;:&quot;Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02195336&quot;,&quot;title&quot;:&quot;dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01063283&quot;,&quot;title&quot;:&quot;Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02195336&quot;,&quot;title&quot;:&quot;dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01218867&quot;,&quot;title&quot;:&quot;Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054052&quot;,&quot;title&quot;:&quot;Intrapleural Bevacizumab Injection for Malignant Pleural Effusion in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00254319&quot;,&quot;title&quot;:&quot;Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01980472&quot;,&quot;title&quot;:&quot;A Phase II Study of Chemotherapy Regimen Plus Bevacizumab in Elderly Non-small Cell Lung Cancer (NSCLC) Patients Selected by Geriatric Assessment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01588704&quot;,&quot;title&quot;:&quot;Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741221&quot;,&quot;title&quot;:&quot;Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01171170&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00150657&quot;,&quot;title&quot;:&quot;Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01705184&quot;,&quot;title&quot;:&quot;Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741195&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00755170&quot;,&quot;title&quot;:&quot;Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01623102&quot;,&quot;title&quot;:&quot;Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01649947&quot;,&quot;title&quot;:&quot;Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753909&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01770171&quot;,&quot;title&quot;:&quot;Carboplatin-Paclitaxel \u00b1 Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951482&quot;,&quot;title&quot;:&quot;Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005120&quot;,&quot;title&quot;:&quot;Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179567&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200354&quot;,&quot;title&quot;:&quot;The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01763645&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02162537&quot;,&quot;title&quot;:&quot;Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01763671&quot;,&quot;title&quot;:&quot;Paclitaxel-bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01351415&quot;,&quot;title&quot;:&quot;A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01107626&quot;,&quot;title&quot;:&quot;Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">41</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ABP-215</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="ABP-215" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ABP-215" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ABP-215" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="ABP-215" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ABP-215" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Anti-VEGFR2 CAR CD8 plus PBL</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Anti-VEGFR2 CAR CD8 plus PBL" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Anti-VEGFR2 CAR CD8 plus PBL" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01218867&quot;,&quot;title&quot;:&quot;Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Anti-VEGFR2 CAR CD8 plus PBL" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anti-VEGFR2 CAR CD8 plus PBL" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anti-VEGFR2 CAR CD8 plus PBL" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BCD-021</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BCD-021" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BCD-021" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCD-021" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01763645&quot;,&quot;title&quot;:&quot;A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BCD-021" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BCD-021" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bevacizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054052&quot;,&quot;title&quot;:&quot;Intrapleural Bevacizumab Injection for Malignant Pleural Effusion in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00254319&quot;,&quot;title&quot;:&quot;Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01980472&quot;,&quot;title&quot;:&quot;A Phase II Study of Chemotherapy Regimen Plus Bevacizumab in Elderly Non-small Cell Lung Cancer (NSCLC) Patients Selected by Geriatric Assessment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01588704&quot;,&quot;title&quot;:&quot;Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741221&quot;,&quot;title&quot;:&quot;Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01171170&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00150657&quot;,&quot;title&quot;:&quot;Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01705184&quot;,&quot;title&quot;:&quot;Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00741195&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01263782&quot;,&quot;title&quot;:&quot;BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00755170&quot;,&quot;title&quot;:&quot;Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01623102&quot;,&quot;title&quot;:&quot;Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01649947&quot;,&quot;title&quot;:&quot;Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01047059&quot;,&quot;title&quot;:&quot;Molecular Imaging With Erlotinib and Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532089&quot;,&quot;title&quot;:&quot;Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01493843&quot;,&quot;title&quot;:&quot;Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01344824&quot;,&quot;title&quot;:&quot;Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01562028&quot;,&quot;title&quot;:&quot;BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753909&quot;,&quot;title&quot;:&quot;Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01770171&quot;,&quot;title&quot;:&quot;Carboplatin-Paclitaxel \u00b1 Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951482&quot;,&quot;title&quot;:&quot;Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005120&quot;,&quot;title&quot;:&quot;Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179567&quot;,&quot;title&quot;:&quot;Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200354&quot;,&quot;title&quot;:&quot;The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">25</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02162537&quot;,&quot;title&quot;:&quot;Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01763671&quot;,&quot;title&quot;:&quot;Paclitaxel-bevacizumab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01351415&quot;,&quot;title&quot;:&quot;A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00946712&quot;,&quot;title&quot;:&quot;S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01107626&quot;,&quot;title&quot;:&quot;Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01966003&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">6</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01063283&quot;,&quot;title&quot;:&quot;Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02195336&quot;,&quot;title&quot;:&quot;dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">34</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cabozatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cabozatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cabozatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588821&quot;,&quot;title&quot;:&quot;Cabozantinib in Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02132598&quot;,&quot;title&quot;:&quot;Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Cabozatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cabozatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lucitanib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02109016&quot;,&quot;title&quot;:&quot;A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lucitanib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ramucirumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ramucirumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ramucirumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ramucirumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ramucirumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ramucirumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Multi kinase inhibitors" data-id="non-small-cell-lung-cancer-nsclc" data-name="multi-kinase-inhibitors_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Multi kinase inhibitors</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01700400&quot;,&quot;title&quot;:&quot;Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01167530&quot;,&quot;title&quot;:&quot;Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01683682&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01684111&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01165385&quot;,&quot;title&quot;:&quot;Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">7</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02038647&quot;,&quot;title&quot;:&quot;Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01924195&quot;,&quot;title&quot;:&quot;Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02029209&quot;,&quot;title&quot;:&quot;To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01948141&quot;,&quot;title&quot;:&quot;Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02152059&quot;,&quot;title&quot;:&quot;A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01262820&quot;,&quot;title&quot;:&quot;Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01179269&quot;,&quot;title&quot;:&quot;Stage IIIB/IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797874&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance for SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01159327&quot;,&quot;title&quot;:&quot;Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01829217&quot;,&quot;title&quot;:&quot;Sunitinib in Never-Smokers With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01019798&quot;,&quot;title&quot;:&quot;Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01210053&quot;,&quot;title&quot;:&quot;Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01850147&quot;,&quot;title&quot;:&quot;Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01823068&quot;,&quot;title&quot;:&quot;Vandetanib in Advanced NSCLC With RET Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">19</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02231164&quot;,&quot;title&quot;:&quot;Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02193152&quot;,&quot;title&quot;:&quot;Pazopanib in Molecularly Selected Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02193152&quot;,&quot;title&quot;:&quot;Pazopanib in Molecularly Selected Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01700400&quot;,&quot;title&quot;:&quot;Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01167530&quot;,&quot;title&quot;:&quot;Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01683682&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01684111&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01165385&quot;,&quot;title&quot;:&quot;Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02038647&quot;,&quot;title&quot;:&quot;Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01924195&quot;,&quot;title&quot;:&quot;Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02029209&quot;,&quot;title&quot;:&quot;To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01948141&quot;,&quot;title&quot;:&quot;Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02152059&quot;,&quot;title&quot;:&quot;A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01262820&quot;,&quot;title&quot;:&quot;Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01179269&quot;,&quot;title&quot;:&quot;Stage IIIB/IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797874&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance for SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01159327&quot;,&quot;title&quot;:&quot;Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01829217&quot;,&quot;title&quot;:&quot;Sunitinib in Never-Smokers With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01019798&quot;,&quot;title&quot;:&quot;Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01210053&quot;,&quot;title&quot;:&quot;Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01850147&quot;,&quot;title&quot;:&quot;Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01823068&quot;,&quot;title&quot;:&quot;Vandetanib in Advanced NSCLC With RET Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02231164&quot;,&quot;title&quot;:&quot;Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">28</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alisertib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Alisertib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Alisertib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02038647&quot;,&quot;title&quot;:&quot;Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Alisertib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Alisertib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Alisertib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Anlotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Anlotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Anlotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01924195&quot;,&quot;title&quot;:&quot;Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02029209&quot;,&quot;title&quot;:&quot;To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Anlotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anlotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anlotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Everolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01700400&quot;,&quot;title&quot;:&quot;Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01167530&quot;,&quot;title&quot;:&quot;Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Everolimus" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lapatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nintedanib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01683682&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01684111&quot;,&quot;title&quot;:&quot;An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01948141&quot;,&quot;title&quot;:&quot;Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02152059&quot;,&quot;title&quot;:&quot;A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02231164&quot;,&quot;title&quot;:&quot;Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pazopanib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01165385&quot;,&quot;title&quot;:&quot;Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01262820&quot;,&quot;title&quot;:&quot;Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01179269&quot;,&quot;title&quot;:&quot;Stage IIIB/IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797874&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance for SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02193152&quot;,&quot;title&quot;:&quot;Pazopanib in Molecularly Selected Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sorafenib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Sorafenib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Sorafenib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00801385&quot;,&quot;title&quot;:&quot;Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01159327&quot;,&quot;title&quot;:&quot;Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01248247&quot;,&quot;title&quot;:&quot;BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Sorafenib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sorafenib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sorafenib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">4</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sunitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01829217&quot;,&quot;title&quot;:&quot;Sunitinib in Never-Smokers With Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01019798&quot;,&quot;title&quot;:&quot;Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01210053&quot;,&quot;title&quot;:&quot;Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01850147&quot;,&quot;title&quot;:&quot;Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">5</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Vandetanib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Vandetanib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01586624&quot;,&quot;title&quot;:&quot;A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vandetanib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01823068&quot;,&quot;title&quot;:&quot;Vandetanib in Advanced NSCLC With RET Rearrangement&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02117167&quot;,&quot;title&quot;:&quot;Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Vandetanib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vandetanib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vandetanib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="NaPi2b" data-id="non-small-cell-lung-cancer-nsclc" data-name="napi2b_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">NaPi2b</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="NaPi2b" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01363947&quot;,&quot;title&quot;:&quot;Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="NaPi2b" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="NaPi2b" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="NaPi2b" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="NaPi2b" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01363947&quot;,&quot;title&quot;:&quot;Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="napi2b_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">DNIB0600A</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="DNIB0600A" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01363947&quot;,&quot;title&quot;:&quot;Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="DNIB0600A" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DNIB0600A" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DNIB0600A" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="DNIB0600A" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PARP" data-id="non-small-cell-lung-cancer-nsclc" data-name="parp_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PARP</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01562210&quot;,&quot;title&quot;:&quot;Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01788332&quot;,&quot;title&quot;:&quot;Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01657799&quot;,&quot;title&quot;:&quot;A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02106546&quot;,&quot;title&quot;:&quot;Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PARP" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01562210&quot;,&quot;title&quot;:&quot;Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01788332&quot;,&quot;title&quot;:&quot;Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01657799&quot;,&quot;title&quot;:&quot;A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02106546&quot;,&quot;title&quot;:&quot;Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td></div></td></tr><tr class="parp_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Olaparib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Olaparib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01562210&quot;,&quot;title&quot;:&quot;Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Olaparib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01788332&quot;,&quot;title&quot;:&quot;Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01513174&quot;,&quot;title&quot;:&quot;Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Olaparib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Olaparib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Olaparib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="parp_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Veliparib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01657799&quot;,&quot;title&quot;:&quot;A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02106546&quot;,&quot;title&quot;:&quot;Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="JAK" data-id="non-small-cell-lung-cancer-nsclc" data-name="jak_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">JAK</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="JAK" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="JAK" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02119650&quot;,&quot;title&quot;:&quot;Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="JAK" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="JAK" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="JAK" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02119650&quot;,&quot;title&quot;:&quot;Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td></div></td></tr><tr class="jak_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Momelotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Momelotinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02206763&quot;,&quot;title&quot;:&quot;Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Momelotinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Momelotinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Momelotinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Momelotinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="jak_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ruxolitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ruxolitinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02145637&quot;,&quot;title&quot;:&quot;Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ruxolitinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02155465&quot;,&quot;title&quot;:&quot;Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02119650&quot;,&quot;title&quot;:&quot;Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Ruxolitinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ruxolitinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ruxolitinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CDK 4/6" data-id="non-small-cell-lung-cancer-nsclc" data-name="cdk-4-6_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CDK 4/6</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK 4/6" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK 4/6" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK 4/6" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="CDK 4/6" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK 4/6" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td></div></td></tr><tr class="cdk-4-6_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LY2835219</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2835219" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02079636&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LY2835219" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2835219" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02152631&quot;,&quot;title&quot;:&quot;A Study of LY2835219 in Participants With Previously Treated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LY2835219" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2835219" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="cdk-4-6_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Palbociclib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Palbociclib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Palbociclib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02022982&quot;,&quot;title&quot;:&quot;PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Palbociclib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Palbociclib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Palbociclib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Histone deacetylase (HDAC/HDI)" data-id="non-small-cell-lung-cancer-nsclc" data-name="histone-deacetylase-hdac-hdi_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Histone deacetylase (HDAC/HDI)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01537744&quot;,&quot;title&quot;:&quot;A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01059552&quot;,&quot;title&quot;:&quot;Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00946673&quot;,&quot;title&quot;:&quot;Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01836679&quot;,&quot;title&quot;:&quot;Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01935947&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00907179&quot;,&quot;title&quot;:&quot;Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td data-content-name="lung-cancer" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01886573&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01886573&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01537744&quot;,&quot;title&quot;:&quot;A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01059552&quot;,&quot;title&quot;:&quot;Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00946673&quot;,&quot;title&quot;:&quot;Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01836679&quot;,&quot;title&quot;:&quot;Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01935947&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00907179&quot;,&quot;title&quot;:&quot;Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">9</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Chidamide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Chidamide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chidamide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01836679&quot;,&quot;title&quot;:&quot;Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Chidamide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Chidamide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Chidamide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Entinostat</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Entinostat" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Entinostat" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935947&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Entinostat" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Entinostat" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01886573&quot;,&quot;title&quot;:&quot;Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Entinostat" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Panobinostat</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Panobinostat" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Panobinostat" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00907179&quot;,&quot;title&quot;:&quot;Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Panobinostat" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Panobinostat" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Panobinostat" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Romidepsin</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Romidepsin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01537744&quot;,&quot;title&quot;:&quot;A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Romidepsin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01302808&quot;,&quot;title&quot;:&quot;Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Romidepsin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Romidepsin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Romidepsin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Vorinostat</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Vorinostat" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01059552&quot;,&quot;title&quot;:&quot;Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00946673&quot;,&quot;title&quot;:&quot;Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Vorinostat" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vorinostat" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vorinostat" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vorinostat" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Proteasome" data-id="non-small-cell-lung-cancer-nsclc" data-name="proteasome_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Proteasome</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00118144&quot;,&quot;title&quot;:&quot;Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00118144&quot;,&quot;title&quot;:&quot;Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="proteasome_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bortezomib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00118144&quot;,&quot;title&quot;:&quot;Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bortezomib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="proteasome_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Carfilzomib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PD-1/PDL-1" data-id="non-small-cell-lung-cancer-nsclc" data-name="pd-1-pdl-1_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PD-1/PDL-1</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PD-1/PDL-1" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02007070&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01840579&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PD-1/PDL-1" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01928576&quot;,&quot;title&quot;:&quot;Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087423&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02031458&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;BIRCH\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175017&quot;,&quot;title&quot;:&quot;ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02085070&quot;,&quot;title&quot;:&quot;MK-3475 in Melanoma and NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PD-1/PDL-1" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125461&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02008227&quot;,&quot;title&quot;:&quot;A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;OAK\&quot;&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02041533&quot;,&quot;title&quot;:&quot;An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator&#x27;s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02066636&quot;,&quot;title&quot;:&quot;A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01905657&quot;,&quot;title&quot;:&quot;Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02220894&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">8</td><td data-content-name="lung-cancer" data-intervention="PD-1/PDL-1" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PD-1/PDL-1" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02007070&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01840579&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01928576&quot;,&quot;title&quot;:&quot;Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087423&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02031458&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;BIRCH\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175017&quot;,&quot;title&quot;:&quot;ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02085070&quot;,&quot;title&quot;:&quot;MK-3475 in Melanoma and NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125461&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02008227&quot;,&quot;title&quot;:&quot;A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;OAK\&quot;&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02041533&quot;,&quot;title&quot;:&quot;An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator&#x27;s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02066636&quot;,&quot;title&quot;:&quot;A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01905657&quot;,&quot;title&quot;:&quot;Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02220894&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">24</td></div></td></tr><tr class="pd-1-pdl-1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CC-486</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="CC-486" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CC-486" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01928576&quot;,&quot;title&quot;:&quot;Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="CC-486" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CC-486" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CC-486" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pd-1-pdl-1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEDI4736</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MEDI4736" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEDI4736" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087423&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEDI4736" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02125461&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="MEDI4736" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MEDI4736" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">7</td></div></td></tr><tr class="pd-1-pdl-1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MPDL3280A</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MPDL3280A" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MPDL3280A" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02031458&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;BIRCH\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MPDL3280A" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02008227&quot;,&quot;title&quot;:&quot;A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;OAK\&quot;&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MPDL3280A" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MPDL3280A" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">4</td></div></td></tr><tr class="pd-1-pdl-1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nivolumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Nivolumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nivolumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02175017&quot;,&quot;title&quot;:&quot;ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nivolumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02041533&quot;,&quot;title&quot;:&quot;An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator&#x27;s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02066636&quot;,&quot;title&quot;:&quot;A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Nivolumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nivolumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">4</td></div></td></tr><tr class="pd-1-pdl-1_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pembrolizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Pembrolizumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02007070&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01840579&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pembrolizumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02085070&quot;,&quot;title&quot;:&quot;MK-3475 in Melanoma and NSCLC Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pembrolizumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01905657&quot;,&quot;title&quot;:&quot;Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02220894&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Pembrolizumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Pembrolizumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">8</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CTLA-4" data-id="non-small-cell-lung-cancer-nsclc" data-name="ctla-4_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CTLA-4</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">5</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01820754&quot;,&quot;title&quot;:&quot;Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02221739&quot;,&quot;title&quot;:&quot;Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01285609&quot;,&quot;title&quot;:&quot;Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01450761&quot;,&quot;title&quot;:&quot;Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01820754&quot;,&quot;title&quot;:&quot;Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02221739&quot;,&quot;title&quot;:&quot;Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01285609&quot;,&quot;title&quot;:&quot;Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01450761&quot;,&quot;title&quot;:&quot;Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">11</td></div></td></tr><tr class="ctla-4_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ipilimumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01820754&quot;,&quot;title&quot;:&quot;Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02221739&quot;,&quot;title&quot;:&quot;Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01285609&quot;,&quot;title&quot;:&quot;Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01450761&quot;,&quot;title&quot;:&quot;Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">8</td></div></td></tr><tr class="ctla-4_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tremelimumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Tremelimumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tremelimumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tremelimumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tremelimumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tremelimumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Other antibodies or immunologics" data-id="non-small-cell-lung-cancer-nsclc" data-name="other-antibodies-or-immunologics_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Other antibodies or immunologics</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Other antibodies or immunologics" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00569296&quot;,&quot;title&quot;:&quot;Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01323062&quot;,&quot;title&quot;:&quot;Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01292655&quot;,&quot;title&quot;:&quot;Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02071862&quot;,&quot;title&quot;:&quot;Study of the Glutaminase Inhibitor CB-839 in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02120807&quot;,&quot;title&quot;:&quot;Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01189968&quot;,&quot;title&quot;:&quot;A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01803282&quot;,&quot;title&quot;:&quot;Safety and Tolerability Study in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02122861&quot;,&quot;title&quot;:&quot;A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01727076&quot;,&quot;title&quot;:&quot;Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02018523&quot;,&quot;title&quot;:&quot;Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01115790&quot;,&quot;title&quot;:&quot;A Phase 1 Study in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01761240&quot;,&quot;title&quot;:&quot;Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02029729&quot;,&quot;title&quot;:&quot;RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC \u0026 Melanoma)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01471210&quot;,&quot;title&quot;:&quot;Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&#x27;s Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">17</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Other antibodies or immunologics" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02087241&quot;,&quot;title&quot;:&quot;Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087176&quot;,&quot;title&quot;:&quot;A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01898156&quot;,&quot;title&quot;:&quot;Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00951444&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951690&quot;,&quot;title&quot;:&quot;Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951586&quot;,&quot;title&quot;:&quot;Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01134250&quot;,&quot;title&quot;:&quot;Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00546130&quot;,&quot;title&quot;:&quot;Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951157&quot;,&quot;title&quot;:&quot;A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200081&quot;,&quot;title&quot;:&quot;Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01859741&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01862900&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01574729&quot;,&quot;title&quot;:&quot;Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01853878&quot;,&quot;title&quot;:&quot;A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02133196&quot;,&quot;title&quot;:&quot;Autologous Young Tumor-Infiltrating Lymphocytes (TIL) From People With Non-Small Cell Lung Cancer Following Preparative Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00874328&quot;,&quot;title&quot;:&quot;A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">17</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Other antibodies or immunologics" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01631357&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01481259&quot;,&quot;title&quot;:&quot;Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02129699&quot;,&quot;title&quot;:&quot;Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01383148&quot;,&quot;title&quot;:&quot;Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049151&quot;,&quot;title&quot;:&quot;Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774578&quot;,&quot;title&quot;:&quot;Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Other antibodies or immunologics" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01801852&quot;,&quot;title&quot;:&quot;Autologous Natural Killer T Cells Infusion for the Treatment of Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Other antibodies or immunologics" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01801852&quot;,&quot;title&quot;:&quot;Autologous Natural Killer T Cells Infusion for the Treatment of Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00569296&quot;,&quot;title&quot;:&quot;Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01323062&quot;,&quot;title&quot;:&quot;Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01292655&quot;,&quot;title&quot;:&quot;Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02071862&quot;,&quot;title&quot;:&quot;Study of the Glutaminase Inhibitor CB-839 in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02120807&quot;,&quot;title&quot;:&quot;Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01189968&quot;,&quot;title&quot;:&quot;A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01803282&quot;,&quot;title&quot;:&quot;Safety and Tolerability Study in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02122861&quot;,&quot;title&quot;:&quot;A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01727076&quot;,&quot;title&quot;:&quot;Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02018523&quot;,&quot;title&quot;:&quot;Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01115790&quot;,&quot;title&quot;:&quot;A Phase 1 Study in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01761240&quot;,&quot;title&quot;:&quot;Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02029729&quot;,&quot;title&quot;:&quot;RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC \u0026 Melanoma)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01471210&quot;,&quot;title&quot;:&quot;Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&#x27;s Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02087241&quot;,&quot;title&quot;:&quot;Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087176&quot;,&quot;title&quot;:&quot;A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01898156&quot;,&quot;title&quot;:&quot;Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00951444&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951690&quot;,&quot;title&quot;:&quot;Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951586&quot;,&quot;title&quot;:&quot;Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01134250&quot;,&quot;title&quot;:&quot;Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00546130&quot;,&quot;title&quot;:&quot;Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01951157&quot;,&quot;title&quot;:&quot;A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200081&quot;,&quot;title&quot;:&quot;Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01859741&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01862900&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01574729&quot;,&quot;title&quot;:&quot;Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01853878&quot;,&quot;title&quot;:&quot;A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02133196&quot;,&quot;title&quot;:&quot;Autologous Young Tumor-Infiltrating Lymphocytes (TIL) From People With Non-Small Cell Lung Cancer Following Preparative Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00874328&quot;,&quot;title&quot;:&quot;A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01631357&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01481259&quot;,&quot;title&quot;:&quot;Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02129699&quot;,&quot;title&quot;:&quot;Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01383148&quot;,&quot;title&quot;:&quot;Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049151&quot;,&quot;title&quot;:&quot;Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01774578&quot;,&quot;title&quot;:&quot;Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">42</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous activated/natural killer t-cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous activated/natural killer t-cells" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00569296&quot;,&quot;title&quot;:&quot;Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Autologous activated/natural killer t-cells" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous activated/natural killer t-cells" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01631357&quot;,&quot;title&quot;:&quot;Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01481259&quot;,&quot;title&quot;:&quot;Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous activated/natural killer t-cells" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01801852&quot;,&quot;title&quot;:&quot;Autologous Natural Killer T Cells Infusion for the Treatment of Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Autologous activated/natural killer t-cells" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">4</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD1775</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="AZD1775" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD1775" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02087241&quot;,&quot;title&quot;:&quot;Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087176&quot;,&quot;title&quot;:&quot;A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="AZD1775" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD1775" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD1775" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bavituximab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Bavituximab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01323062&quot;,&quot;title&quot;:&quot;Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Bavituximab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bavituximab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bavituximab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bavituximab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BIW-8962</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BIW-8962" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BIW-8962" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01898156&quot;,&quot;title&quot;:&quot;Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BIW-8962" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BIW-8962" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BIW-8962" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BMS-906024</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="BMS-906024" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01292655&quot;,&quot;title&quot;:&quot;Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BMS-906024" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BMS-906024" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BMS-906024" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BMS-906024" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CB-839</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="CB-839" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02071862&quot;,&quot;title&quot;:&quot;Study of the Glutaminase Inhibitor CB-839 in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="CB-839" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CB-839" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CB-839" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CB-839" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Certolizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Certolizumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02120807&quot;,&quot;title&quot;:&quot;Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Certolizumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Certolizumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Certolizumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Certolizumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cilengitide</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dalotuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Dalotuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dalotuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00951444&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Dalotuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dalotuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dalotuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Defactinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Defactinib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Defactinib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01951690&quot;,&quot;title&quot;:&quot;Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Defactinib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Defactinib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Defactinib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Demcizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Demcizumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189968&quot;,&quot;title&quot;:&quot;A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Demcizumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Demcizumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Demcizumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Demcizumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Denosumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Denosumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Denosumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01951586&quot;,&quot;title&quot;:&quot;Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Denosumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02129699&quot;,&quot;title&quot;:&quot;Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Denosumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Denosumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GS-5745</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="GS-5745" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01803282&quot;,&quot;title&quot;:&quot;Safety and Tolerability Study in Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GS-5745" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GS-5745" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GS-5745" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GS-5745" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ID-LV305</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="ID-LV305" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02122861&quot;,&quot;title&quot;:&quot;A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="ID-LV305" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ID-LV305" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ID-LV305" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ID-LV305" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">IGF-1</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="IGF-1" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02191891&quot;,&quot;title&quot;:&quot;BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="IGF-1" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="IGF-1" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="IGF-1" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="IGF-1" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">INCB024360</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="INCB024360" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="INCB024360" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="INCB024360" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="INCB024360" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="INCB024360" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Interferon alfa-2b</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Interferon alfa-2b" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Interferon alfa-2b" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Interferon alfa-2b" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Interferon alfa-2b" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Interferon alfa-2b" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Interleukins</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Interleukins" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01727076&quot;,&quot;title&quot;:&quot;Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Interleukins" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01134250&quot;,&quot;title&quot;:&quot;Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Interleukins" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01383148&quot;,&quot;title&quot;:&quot;Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Interleukins" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Interleukins" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">3</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Irinotecan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Irinotecan" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Irinotecan" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00546130&quot;,&quot;title&quot;:&quot;Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Irinotecan" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Irinotecan" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Irinotecan" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lenalidomide</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Lenalidomide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02018523&quot;,&quot;title&quot;:&quot;Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lenalidomide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lenalidomide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lenalidomide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lenalidomide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lurbinectedin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lurbinectedin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lurbinectedin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01951157&quot;,&quot;title&quot;:&quot;A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lurbinectedin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lurbinectedin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lurbinectedin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LY2606368</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2606368" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01115790&quot;,&quot;title&quot;:&quot;A Phase 1 Study in Participants With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LY2606368" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2606368" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2606368" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2606368" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MORab-066</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MORab-066" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01761240&quot;,&quot;title&quot;:&quot;Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MORab-066" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MORab-066" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MORab-066" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MORab-066" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MGN1703</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MGN1703" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MGN1703" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02200081&quot;,&quot;title&quot;:&quot;Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MGN1703" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGN1703" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MGN1703" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">OMP-59R5</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="OMP-59R5" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="OMP-59R5" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01859741&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="OMP-59R5" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OMP-59R5" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OMP-59R5" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">OX40</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="OX40" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="OX40" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01862900&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="OX40" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OX40" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OX40" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">rAd-p53 gene therapy</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="rAd-p53 gene therapy" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="rAd-p53 gene therapy" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01574729&quot;,&quot;title&quot;:&quot;Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="rAd-p53 gene therapy" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="rAd-p53 gene therapy" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="rAd-p53 gene therapy" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Rilotumumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Rilotumumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Rilotumumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Rilotumumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">RTA-408</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="RTA-408" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02029729&quot;,&quot;title&quot;:&quot;RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC \u0026 Melanoma)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="RTA-408" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RTA-408" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RTA-408" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="RTA-408" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PRAME (Preferentially Expressed Antigen of Melanoma)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="PRAME (Preferentially Expressed Antigen of Melanoma)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PRAME (Preferentially Expressed Antigen of Melanoma)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01853878&quot;,&quot;title&quot;:&quot;A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PRAME (Preferentially Expressed Antigen of Melanoma)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PRAME (Preferentially Expressed Antigen of Melanoma)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PRAME (Preferentially Expressed Antigen of Melanoma)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tecemotide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02049151&quot;,&quot;title&quot;:&quot;Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tergenpumatucel-L</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Tergenpumatucel-L" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tergenpumatucel-L" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tergenpumatucel-L" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01774578&quot;,&quot;title&quot;:&quot;Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tergenpumatucel-L" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tergenpumatucel-L" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">TILS</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="TILS" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="TILS" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02133196&quot;,&quot;title&quot;:&quot;Autologous Young Tumor-Infiltrating Lymphocytes (TIL) From People With Non-Small Cell Lung Cancer Following Preparative Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="TILS" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="TILS" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="TILS" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">TS-1</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="TS-1" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="TS-1" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00874328&quot;,&quot;title&quot;:&quot;A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="TS-1" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="TS-1" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="TS-1" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Urelumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Urelumab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01471210&quot;,&quot;title&quot;:&quot;Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&#x27;s Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Urelumab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Urelumab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Urelumab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Urelumab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="null">1</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Vaccines</td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Ad/HER2/Neu Dendritic Cell Cancer Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ad/HER2/Neu Dendritic Cell Cancer Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01730118&quot;,&quot;title&quot;:&quot;Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ad/HER2/Neu Dendritic Cell Cancer Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ad/HER2/Neu Dendritic Cell Cancer Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ad/HER2/Neu Dendritic Cell Cancer Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ad/HER2/Neu Dendritic Cell Cancer Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01730118&quot;,&quot;title&quot;:&quot;Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Allogeneic Tumor Cell Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Allogeneic Tumor Cell Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Allogeneic Tumor Cell Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00722228&quot;,&quot;title&quot;:&quot;Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Allogeneic Tumor Cell Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Allogeneic Tumor Cell Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Allogeneic Tumor Cell Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00722228&quot;,&quot;title&quot;:&quot;Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Autologous tumor cell vaccine + ISCOMATRIX adjuvant</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01258868&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01258868&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">AVX901</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AVX901" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01526473&quot;,&quot;title&quot;:&quot;A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AVX901" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AVX901" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AVX901" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AVX901" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01526473&quot;,&quot;title&quot;:&quot;A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">BLP25 Liposome Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BLP25 Liposome Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BLP25 Liposome Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00828009&quot;,&quot;title&quot;:&quot;BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BLP25 Liposome Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BLP25 Liposome Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BLP25 Liposome Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00828009&quot;,&quot;title&quot;:&quot;BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Combination Vaccine Immunotherapy (DRibbles)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Combination Vaccine Immunotherapy (DRibbles)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Combination Vaccine Immunotherapy (DRibbles)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01909752&quot;,&quot;title&quot;:&quot;Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Combination Vaccine Immunotherapy (DRibbles)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Combination Vaccine Immunotherapy (DRibbles)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Combination Vaccine Immunotherapy (DRibbles)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01909752&quot;,&quot;title&quot;:&quot;Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">CV9202</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="CV9202" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01915524&quot;,&quot;title&quot;:&quot;Trial of RNActive\u00ae-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="CV9202" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CV9202" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CV9202" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CV9202" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01915524&quot;,&quot;title&quot;:&quot;Trial of RNActive\u00ae-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Dex2</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Dex2" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dex2" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01159288&quot;,&quot;title&quot;:&quot;Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Dex2" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Dex2" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Dex2" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01159288&quot;,&quot;title&quot;:&quot;Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">EGF Cancer Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="EGF Cancer Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="EGF Cancer Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGF Cancer Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02187367&quot;,&quot;title&quot;:&quot;Safety \u0026 Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="EGF Cancer Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGF Cancer Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02187367&quot;,&quot;title&quot;:&quot;Safety \u0026 Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">GM.CD40L</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="GM.CD40L" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GM.CD40L" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01433172&quot;,&quot;title&quot;:&quot;Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GM.CD40L" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GM.CD40L" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GM.CD40L" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01433172&quot;,&quot;title&quot;:&quot;Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">gp96-Ig Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="gp96-Ig Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01799161&quot;,&quot;title&quot;:&quot;Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="gp96-Ig Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="gp96-Ig Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="gp96-Ig Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="gp96-Ig Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01799161&quot;,&quot;title&quot;:&quot;Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">GV1001</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="GV1001" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GV1001" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GV1001" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579188&quot;,&quot;title&quot;:&quot;Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GV1001" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GV1001" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579188&quot;,&quot;title&quot;:&quot;Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">H1299 cell lysate</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">HLA-A*0201 or HLA-A*0206-restricted URLC10</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*0201 or HLA-A*0206-restricted URLC10" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069640&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*0201 or HLA-A*0206-restricted URLC10" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00673777&quot;,&quot;title&quot;:&quot;Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01949701&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="HLA-A*0201 or HLA-A*0206-restricted URLC10" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HLA-A*0201 or HLA-A*0206-restricted URLC10" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*0201 or HLA-A*0206-restricted URLC10" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069640&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00673777&quot;,&quot;title&quot;:&quot;Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01949701&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069575&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00674258&quot;,&quot;title&quot;:&quot;Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01950156&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069575&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00674258&quot;,&quot;title&quot;:&quot;Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01950156&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Hsp70-peptide TKD/IL-2 activated, autologous NK cells</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Hsp70-peptide TKD/IL-2 activated, autologous NK cells" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hsp70-peptide TKD/IL-2 activated, autologous NK cells" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02118415&quot;,&quot;title&quot;:&quot;Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Hsp70-peptide TKD/IL-2 activated, autologous NK cells" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Hsp70-peptide TKD/IL-2 activated, autologous NK cells" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hsp70-peptide TKD/IL-2 activated, autologous NK cells" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02118415&quot;,&quot;title&quot;:&quot;Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">MUC1 Peptide Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MUC1 Peptide Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02140996&quot;,&quot;title&quot;:&quot;Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MUC1 Peptide Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01720836&quot;,&quot;title&quot;:&quot;Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MUC1 Peptide Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MUC1 Peptide Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MUC1 Peptide Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02140996&quot;,&quot;title&quot;:&quot;Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01720836&quot;,&quot;title&quot;:&quot;Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">NY-ESO-1 With GLA-SE</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="NY-ESO-1 With GLA-SE" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02015416&quot;,&quot;title&quot;:&quot;A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="NY-ESO-1 With GLA-SE" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="NY-ESO-1 With GLA-SE" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="NY-ESO-1 With GLA-SE" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="NY-ESO-1 With GLA-SE" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02015416&quot;,&quot;title&quot;:&quot;A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">OrienX010</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="OrienX010" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935453&quot;,&quot;title&quot;:&quot;A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="OrienX010" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OrienX010" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="OrienX010" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="OrienX010" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935453&quot;,&quot;title&quot;:&quot;A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Racotumomab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Racotumomab" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Racotumomab" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Racotumomab" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01460472&quot;,&quot;title&quot;:&quot;Immunotherapy With Racotumomab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Racotumomab" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Racotumomab" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01460472&quot;,&quot;title&quot;:&quot;Immunotherapy With Racotumomab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Semi-allogeneic human fibroblasts</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Semi-allogeneic human fibroblasts" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00793208&quot;,&quot;title&quot;:&quot;Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Semi-allogeneic human fibroblasts" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Semi-allogeneic human fibroblasts" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Semi-allogeneic human fibroblasts" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Semi-allogeneic human fibroblasts" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00793208&quot;,&quot;title&quot;:&quot;Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Tecemotide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01015443&quot;,&quot;title&quot;:&quot;Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tecemotide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01015443&quot;,&quot;title&quot;:&quot;Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">recombinant adenovirus (Ad/L523S)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="recombinant adenovirus (Ad/L523S)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00062907&quot;,&quot;title&quot;:&quot;Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="recombinant adenovirus (Ad/L523S)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="recombinant adenovirus (Ad/L523S)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="recombinant adenovirus (Ad/L523S)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="recombinant adenovirus (Ad/L523S)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00062907&quot;,&quot;title&quot;:&quot;Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">recombinant DNA (pVAX/L523S)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="recombinant DNA (pVAX/L523S)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00062907&quot;,&quot;title&quot;:&quot;Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="recombinant DNA (pVAX/L523S)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="recombinant DNA (pVAX/L523S)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="recombinant DNA (pVAX/L523S)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="recombinant DNA (pVAX/L523S)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00062907&quot;,&quot;title&quot;:&quot;Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">UV1 synthetic peptide vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="UV1 synthetic peptide vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="UV1 synthetic peptide vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01789099&quot;,&quot;title&quot;:&quot;A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="UV1 synthetic peptide vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="UV1 synthetic peptide vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="UV1 synthetic peptide vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01789099&quot;,&quot;title&quot;:&quot;A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Vx001</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Vx001" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vx001" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935154&quot;,&quot;title&quot;:&quot;Efficacy Study of Vx001 Vaccine in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Vx001" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vx001" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vx001" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935154&quot;,&quot;title&quot;:&quot;Efficacy Study of Vx001 Vaccine in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Chemotherapy, Radiation, &amp; Surgery</td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Chemotherapy</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Chemotherapy" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01014598&quot;,&quot;title&quot;:&quot;Cisplatin in Treating Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00846443&quot;,&quot;title&quot;:&quot;Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00985998&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00856037&quot;,&quot;title&quot;:&quot;Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00926640&quot;,&quot;title&quot;:&quot;A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01664754&quot;,&quot;title&quot;:&quot;Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01772732&quot;,&quot;title&quot;:&quot;Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02225405&quot;,&quot;title&quot;:&quot;Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chemotherapy" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168883&quot;,&quot;title&quot;:&quot;Study for Patients With Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00906061&quot;,&quot;title&quot;:&quot;Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01424709&quot;,&quot;title&quot;:&quot;Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01497041&quot;,&quot;title&quot;:&quot;A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02045446&quot;,&quot;title&quot;:&quot;Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01296113&quot;,&quot;title&quot;:&quot;Chemotherapy for Lung Cancer in HIV-positive Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00940069&quot;,&quot;title&quot;:&quot;TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797913&quot;,&quot;title&quot;:&quot;The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00755170&quot;,&quot;title&quot;:&quot;Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01969955&quot;,&quot;title&quot;:&quot;Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01623102&quot;,&quot;title&quot;:&quot;Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01054482&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01649947&quot;,&quot;title&quot;:&quot;Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00602797&quot;,&quot;title&quot;:&quot;Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01438307&quot;,&quot;title&quot;:&quot;Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00178698&quot;,&quot;title&quot;:&quot;Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00238849&quot;,&quot;title&quot;:&quot;Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00270582&quot;,&quot;title&quot;:&quot;A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00398385&quot;,&quot;title&quot;:&quot;Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00449657&quot;,&quot;title&quot;:&quot;Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, \u0026 Adjuvant Chemo in Stage III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00514293&quot;,&quot;title&quot;:&quot;Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616031&quot;,&quot;title&quot;:&quot;Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616785&quot;,&quot;title&quot;:&quot;Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00625352&quot;,&quot;title&quot;:&quot;Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00736814&quot;,&quot;title&quot;:&quot;First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00759824&quot;,&quot;title&quot;:&quot;A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00786331&quot;,&quot;title&quot;:&quot;Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00853684&quot;,&quot;title&quot;:&quot;Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923637&quot;,&quot;title&quot;:&quot;Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01051362&quot;,&quot;title&quot;:&quot;Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01066234&quot;,&quot;title&quot;:&quot;Adjuvant CCRT vs CT in Minimal N2 NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01088906&quot;,&quot;title&quot;:&quot;Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01097317&quot;,&quot;title&quot;:&quot;First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01187290&quot;,&quot;title&quot;:&quot;Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01356303&quot;,&quot;title&quot;:&quot;Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01401192&quot;,&quot;title&quot;:&quot;Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01494415&quot;,&quot;title&quot;:&quot;Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01624051&quot;,&quot;title&quot;:&quot;A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01628471&quot;,&quot;title&quot;:&quot;MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01635400&quot;,&quot;title&quot;:&quot;Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648517&quot;,&quot;title&quot;:&quot;Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 \u0026 RRM1 as First-line Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01660399&quot;,&quot;title&quot;:&quot;Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01702844&quot;,&quot;title&quot;:&quot;Single Arm on the Tolerability of Weekly Nab-paclitaxel&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01725165&quot;,&quot;title&quot;:&quot;Oligometastatic Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01742767&quot;,&quot;title&quot;:&quot;Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01757288&quot;,&quot;title&quot;:&quot;A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01771289&quot;,&quot;title&quot;:&quot;Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01773109&quot;,&quot;title&quot;:&quot;Etirinotecan Pegol (NKTR-102) in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01784107&quot;,&quot;title&quot;:&quot;A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01784549&quot;,&quot;title&quot;:&quot;Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01792479&quot;,&quot;title&quot;:&quot;A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01803269&quot;,&quot;title&quot;:&quot;Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01810367&quot;,&quot;title&quot;:&quot;ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01860040&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemo for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01872403&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage \u2161 B and IIIA Squamous Cell Carcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01872416&quot;,&quot;title&quot;:&quot;A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01926483&quot;,&quot;title&quot;:&quot;Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977235&quot;,&quot;title&quot;:&quot;Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02016209&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039518&quot;,&quot;title&quot;:&quot;Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054819&quot;,&quot;title&quot;:&quot;Treating NSCLC Minimal Stage IV With Curative Intent&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094560&quot;,&quot;title&quot;:&quot;CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02133677&quot;,&quot;title&quot;:&quot;A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134990&quot;,&quot;title&quot;:&quot;Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02166658&quot;,&quot;title&quot;:&quot;A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175381&quot;,&quot;title&quot;:&quot;Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02176369&quot;,&quot;title&quot;:&quot;Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179528&quot;,&quot;title&quot;:&quot;Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200757&quot;,&quot;title&quot;:&quot;Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02223611&quot;,&quot;title&quot;:&quot;Clinical Observation of S1 Capsule for Stage \u2161-\u2162A Non-small Cell Lung Cancer After Complete Resection&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">70</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chemotherapy" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02058433&quot;,&quot;title&quot;:&quot;Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01405586&quot;,&quot;title&quot;:&quot;MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01593293&quot;,&quot;title&quot;:&quot;Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01631136&quot;,&quot;title&quot;:&quot;Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00112710&quot;,&quot;title&quot;:&quot;Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00139971&quot;,&quot;title&quot;:&quot;Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00265694&quot;,&quot;title&quot;:&quot;Random Trial for Elderly Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00478699&quot;,&quot;title&quot;:&quot;Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00551733&quot;,&quot;title&quot;:&quot;Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00617656&quot;,&quot;title&quot;:&quot;Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00658580&quot;,&quot;title&quot;:&quot;Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00683514&quot;,&quot;title&quot;:&quot;Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01204307&quot;,&quot;title&quot;:&quot;Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01257139&quot;,&quot;title&quot;:&quot;Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a \&quot;Classical\&quot; Strategy of Treatment Allocation, With an\&quot;Optimized\&quot; Strategy Allocating the Same Treatments&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01282151&quot;,&quot;title&quot;:&quot;TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01326767&quot;,&quot;title&quot;:&quot;Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01560195&quot;,&quot;title&quot;:&quot;A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01850303&quot;,&quot;title&quot;:&quot;MODEL (Maintenance Versus Observation After inDuction Chemotherapy in Non-progressing Elderly Patients With Advanced Non-small Cell Lung Cancer)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01947062&quot;,&quot;title&quot;:&quot;Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02004184&quot;,&quot;title&quot;:&quot;Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02027428&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">21</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chemotherapy" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336192&quot;,&quot;title&quot;:&quot;Maintenance Gemcitabine in the Chinese Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01261299&quot;,&quot;title&quot;:&quot;Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01874678&quot;,&quot;title&quot;:&quot;A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00864266&quot;,&quot;title&quot;:&quot;Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01211002&quot;,&quot;title&quot;:&quot;Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01493011&quot;,&quot;title&quot;:&quot;Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01848613&quot;,&quot;title&quot;:&quot;Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01860508&quot;,&quot;title&quot;:&quot;A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01891123&quot;,&quot;title&quot;:&quot;Detect the Plasma Drug Concentration of Docetaxel and Paclitaxel, and Explore the Pharmacokinetically-guided Dosing Strategy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01924416&quot;,&quot;title&quot;:&quot;Lung Cancer Information Study (LCIS-R01)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02011087&quot;,&quot;title&quot;:&quot;Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02088515&quot;,&quot;title&quot;:&quot;Nedaplatin (Jiebaishu\u00ae) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02145078&quot;,&quot;title&quot;:&quot;Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02151149&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly&quot;,&quot;phase&quot;:&quot;other&quot;}]">14</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chemotherapy" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01336192&quot;,&quot;title&quot;:&quot;Maintenance Gemcitabine in the Chinese Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01261299&quot;,&quot;title&quot;:&quot;Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01874678&quot;,&quot;title&quot;:&quot;A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00864266&quot;,&quot;title&quot;:&quot;Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01211002&quot;,&quot;title&quot;:&quot;Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01493011&quot;,&quot;title&quot;:&quot;Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01848613&quot;,&quot;title&quot;:&quot;Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01860508&quot;,&quot;title&quot;:&quot;A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01891123&quot;,&quot;title&quot;:&quot;Detect the Plasma Drug Concentration of Docetaxel and Paclitaxel, and Explore the Pharmacokinetically-guided Dosing Strategy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01924416&quot;,&quot;title&quot;:&quot;Lung Cancer Information Study (LCIS-R01)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02011087&quot;,&quot;title&quot;:&quot;Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02088515&quot;,&quot;title&quot;:&quot;Nedaplatin (Jiebaishu\u00ae) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02145078&quot;,&quot;title&quot;:&quot;Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02151149&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01014598&quot;,&quot;title&quot;:&quot;Cisplatin in Treating Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00846443&quot;,&quot;title&quot;:&quot;Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00985998&quot;,&quot;title&quot;:&quot;Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00856037&quot;,&quot;title&quot;:&quot;Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00926640&quot;,&quot;title&quot;:&quot;A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01664754&quot;,&quot;title&quot;:&quot;Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01772732&quot;,&quot;title&quot;:&quot;Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02225405&quot;,&quot;title&quot;:&quot;Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00168883&quot;,&quot;title&quot;:&quot;Study for Patients With Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00906061&quot;,&quot;title&quot;:&quot;Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01424709&quot;,&quot;title&quot;:&quot;Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01497041&quot;,&quot;title&quot;:&quot;A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02045446&quot;,&quot;title&quot;:&quot;Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01296113&quot;,&quot;title&quot;:&quot;Chemotherapy for Lung Cancer in HIV-positive Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00940069&quot;,&quot;title&quot;:&quot;TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797913&quot;,&quot;title&quot;:&quot;The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00755170&quot;,&quot;title&quot;:&quot;Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01969955&quot;,&quot;title&quot;:&quot;Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01623102&quot;,&quot;title&quot;:&quot;Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01054482&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01649947&quot;,&quot;title&quot;:&quot;Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00602797&quot;,&quot;title&quot;:&quot;Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01438307&quot;,&quot;title&quot;:&quot;Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00178698&quot;,&quot;title&quot;:&quot;Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00238849&quot;,&quot;title&quot;:&quot;Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00270582&quot;,&quot;title&quot;:&quot;A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00398385&quot;,&quot;title&quot;:&quot;Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00449657&quot;,&quot;title&quot;:&quot;Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, \u0026 Adjuvant Chemo in Stage III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00514293&quot;,&quot;title&quot;:&quot;Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616031&quot;,&quot;title&quot;:&quot;Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00616785&quot;,&quot;title&quot;:&quot;Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00625352&quot;,&quot;title&quot;:&quot;Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00736814&quot;,&quot;title&quot;:&quot;First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00759824&quot;,&quot;title&quot;:&quot;A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00786331&quot;,&quot;title&quot;:&quot;Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00853684&quot;,&quot;title&quot;:&quot;Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923637&quot;,&quot;title&quot;:&quot;Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01051362&quot;,&quot;title&quot;:&quot;Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01066234&quot;,&quot;title&quot;:&quot;Adjuvant CCRT vs CT in Minimal N2 NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01088906&quot;,&quot;title&quot;:&quot;Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01097317&quot;,&quot;title&quot;:&quot;First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01187290&quot;,&quot;title&quot;:&quot;Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01356303&quot;,&quot;title&quot;:&quot;Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01401192&quot;,&quot;title&quot;:&quot;Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01494415&quot;,&quot;title&quot;:&quot;Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01624051&quot;,&quot;title&quot;:&quot;A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01628471&quot;,&quot;title&quot;:&quot;MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01635400&quot;,&quot;title&quot;:&quot;Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648517&quot;,&quot;title&quot;:&quot;Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 \u0026 RRM1 as First-line Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01660399&quot;,&quot;title&quot;:&quot;Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01702844&quot;,&quot;title&quot;:&quot;Single Arm on the Tolerability of Weekly Nab-paclitaxel&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01725165&quot;,&quot;title&quot;:&quot;Oligometastatic Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01742767&quot;,&quot;title&quot;:&quot;Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01757288&quot;,&quot;title&quot;:&quot;A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01771289&quot;,&quot;title&quot;:&quot;Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01773109&quot;,&quot;title&quot;:&quot;Etirinotecan Pegol (NKTR-102) in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01784107&quot;,&quot;title&quot;:&quot;A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01784549&quot;,&quot;title&quot;:&quot;Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01792479&quot;,&quot;title&quot;:&quot;A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01803269&quot;,&quot;title&quot;:&quot;Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01810367&quot;,&quot;title&quot;:&quot;ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01860040&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemo for NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01872403&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage \u2161 B and IIIA Squamous Cell Carcinoma of the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01872416&quot;,&quot;title&quot;:&quot;A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01926483&quot;,&quot;title&quot;:&quot;Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977235&quot;,&quot;title&quot;:&quot;Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02016209&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039518&quot;,&quot;title&quot;:&quot;Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054819&quot;,&quot;title&quot;:&quot;Treating NSCLC Minimal Stage IV With Curative Intent&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094560&quot;,&quot;title&quot;:&quot;CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02133677&quot;,&quot;title&quot;:&quot;A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02134990&quot;,&quot;title&quot;:&quot;Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02166658&quot;,&quot;title&quot;:&quot;A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175381&quot;,&quot;title&quot;:&quot;Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02176369&quot;,&quot;title&quot;:&quot;Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179528&quot;,&quot;title&quot;:&quot;Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200757&quot;,&quot;title&quot;:&quot;Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02223611&quot;,&quot;title&quot;:&quot;Clinical Observation of S1 Capsule for Stage \u2161-\u2162A Non-small Cell Lung Cancer After Complete Resection&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02058433&quot;,&quot;title&quot;:&quot;Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01405586&quot;,&quot;title&quot;:&quot;MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01593293&quot;,&quot;title&quot;:&quot;Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01631136&quot;,&quot;title&quot;:&quot;Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00112710&quot;,&quot;title&quot;:&quot;Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00139971&quot;,&quot;title&quot;:&quot;Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00265694&quot;,&quot;title&quot;:&quot;Random Trial for Elderly Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00478699&quot;,&quot;title&quot;:&quot;Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00551733&quot;,&quot;title&quot;:&quot;Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00617656&quot;,&quot;title&quot;:&quot;Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00658580&quot;,&quot;title&quot;:&quot;Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00683514&quot;,&quot;title&quot;:&quot;Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01204307&quot;,&quot;title&quot;:&quot;Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01257139&quot;,&quot;title&quot;:&quot;Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a \&quot;Classical\&quot; Strategy of Treatment Allocation, With an\&quot;Optimized\&quot; Strategy Allocating the Same Treatments&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01282151&quot;,&quot;title&quot;:&quot;TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01326767&quot;,&quot;title&quot;:&quot;Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01560195&quot;,&quot;title&quot;:&quot;A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01850303&quot;,&quot;title&quot;:&quot;MODEL (Maintenance Versus Observation After inDuction Chemotherapy in Non-progressing Elderly Patients With Advanced Non-small Cell Lung Cancer)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01947062&quot;,&quot;title&quot;:&quot;Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02004184&quot;,&quot;title&quot;:&quot;Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02027428&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">113</td></div></td></tr><tr class=""><td><div><img alt="radiation" height="24" src="../assets/icon-radiation-2142d7789fc4a2dc44afd5eaa933d211.png" width="24" /><span class="intervention">Radiation</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01108666&quot;,&quot;title&quot;:&quot;Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01167530&quot;,&quot;title&quot;:&quot;Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00264602&quot;,&quot;title&quot;:&quot;Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00846443&quot;,&quot;title&quot;:&quot;Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01899989&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00955942&quot;,&quot;title&quot;:&quot;Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01411098&quot;,&quot;title&quot;:&quot;Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01565772&quot;,&quot;title&quot;:&quot;Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01575782&quot;,&quot;title&quot;:&quot;Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01711697&quot;,&quot;title&quot;:&quot;Standard Radiation Therapy Combined With High Dose, Ablative Radiation in Patients With Advanced Lung Cancer That Cannot be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01933568&quot;,&quot;title&quot;:&quot;Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01958372&quot;,&quot;title&quot;:&quot;Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02059967&quot;,&quot;title&quot;:&quot;Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02172846&quot;,&quot;title&quot;:&quot;Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">15</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00351962&quot;,&quot;title&quot;:&quot;Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01102231&quot;,&quot;title&quot;:&quot;Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01636934&quot;,&quot;title&quot;:&quot;Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00379717&quot;,&quot;title&quot;:&quot;Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01755624&quot;,&quot;title&quot;:&quot;Effect of NovoTTF-100A in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391260&quot;,&quot;title&quot;:&quot;Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01503385&quot;,&quot;title&quot;:&quot;Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00452803&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01166204&quot;,&quot;title&quot;:&quot;Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02045446&quot;,&quot;title&quot;:&quot;Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01657799&quot;,&quot;title&quot;:&quot;A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01603849&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01823003&quot;,&quot;title&quot;:&quot;Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00888511&quot;,&quot;title&quot;:&quot;Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01300299&quot;,&quot;title&quot;:&quot;STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00973310&quot;,&quot;title&quot;:&quot;Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01221675&quot;,&quot;title&quot;:&quot;TF2- Small Cell Lung Cancer Radio Immunotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01185639&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00881712&quot;,&quot;title&quot;:&quot;Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01656460&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00875901&quot;,&quot;title&quot;:&quot;Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00938418&quot;,&quot;title&quot;:&quot;Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871454&quot;,&quot;title&quot;:&quot;Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00466089&quot;,&quot;title&quot;:&quot;Study of 3D Radiotherapy With or Without Erlotinib (Tarceva\u00ae) in Patients With Localized Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00591838&quot;,&quot;title&quot;:&quot;A Phase I/II Trial of Stereotactic Body Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00697333&quot;,&quot;title&quot;:&quot;Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00727350&quot;,&quot;title&quot;:&quot;Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00843726&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01024829&quot;,&quot;title&quot;:&quot;Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01029678&quot;,&quot;title&quot;:&quot;Concomitant Radio-chemotherapy in the Elderly&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01051037&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01076231&quot;,&quot;title&quot;:&quot;Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01166191&quot;,&quot;title&quot;:&quot;Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01507428&quot;,&quot;title&quot;:&quot;Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01518621&quot;,&quot;title&quot;:&quot;Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01537991&quot;,&quot;title&quot;:&quot;ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01543672&quot;,&quot;title&quot;:&quot;Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553916&quot;,&quot;title&quot;:&quot;Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01576796&quot;,&quot;title&quot;:&quot;Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01577212&quot;,&quot;title&quot;:&quot;Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01635270&quot;,&quot;title&quot;:&quot;Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01710956&quot;,&quot;title&quot;:&quot;Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01795521&quot;,&quot;title&quot;:&quot;LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01803542&quot;,&quot;title&quot;:&quot;Stereotactic Radiotherapy (SBRT) of Lung Metastasis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01965223&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy in Lung Metastases From Any Non Haematological Primary Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02002052&quot;,&quot;title&quot;:&quot;Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02014545&quot;,&quot;title&quot;:&quot;Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02058056&quot;,&quot;title&quot;:&quot;Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073968&quot;,&quot;title&quot;:&quot;PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02136355&quot;,&quot;title&quot;:&quot;A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02189967&quot;,&quot;title&quot;:&quot;Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02224547&quot;,&quot;title&quot;:&quot;Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">52</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02076477&quot;,&quot;title&quot;:&quot;The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02162537&quot;,&quot;title&quot;:&quot;Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01014130&quot;,&quot;title&quot;:&quot;Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00633568&quot;,&quot;title&quot;:&quot;Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049151&quot;,&quot;title&quot;:&quot;Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01968941&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01351116&quot;,&quot;title&quot;:&quot;A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01993810&quot;,&quot;title&quot;:&quot;Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01394679&quot;,&quot;title&quot;:&quot;A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00410683&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00632853&quot;,&quot;title&quot;:&quot;Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00880971&quot;,&quot;title&quot;:&quot;To Evaluate Postoperative 3D Conform Radiotherapy in Patients With IIIA (N2) Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00955695&quot;,&quot;title&quot;:&quot;Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01185132&quot;,&quot;title&quot;:&quot;Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459497&quot;,&quot;title&quot;:&quot;Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01780675&quot;,&quot;title&quot;:&quot;Hippocampus Avoidance PCI vs PCI&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">17</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01799135&quot;,&quot;title&quot;:&quot;Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01836692&quot;,&quot;title&quot;:&quot;Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01201044&quot;,&quot;title&quot;:&quot;Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02132143&quot;,&quot;title&quot;:&quot;Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00751543&quot;,&quot;title&quot;:&quot;The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01982123&quot;,&quot;title&quot;:&quot;SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01745484&quot;,&quot;title&quot;:&quot;Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01527058&quot;,&quot;title&quot;:&quot;68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01480973&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01500876&quot;,&quot;title&quot;:&quot;A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01525446&quot;,&quot;title&quot;:&quot;Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02111681&quot;,&quot;title&quot;:&quot;Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01647334&quot;,&quot;title&quot;:&quot;Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01757158&quot;,&quot;title&quot;:&quot;Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01421953&quot;,&quot;title&quot;:&quot;Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01345851&quot;,&quot;title&quot;:&quot;Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01781741&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01946100&quot;,&quot;title&quot;:&quot;Treatment of Multifocal Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02017925&quot;,&quot;title&quot;:&quot;Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02067858&quot;,&quot;title&quot;:&quot;An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM\u2122) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02123888&quot;,&quot;title&quot;:&quot;Simultaneous CBCT Acquisition During Arc Radiotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02130427&quot;,&quot;title&quot;:&quot;A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy&quot;,&quot;phase&quot;:&quot;other&quot;}]">22</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01799135&quot;,&quot;title&quot;:&quot;Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01836692&quot;,&quot;title&quot;:&quot;Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01201044&quot;,&quot;title&quot;:&quot;Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02132143&quot;,&quot;title&quot;:&quot;Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00751543&quot;,&quot;title&quot;:&quot;The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01982123&quot;,&quot;title&quot;:&quot;SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01745484&quot;,&quot;title&quot;:&quot;Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01527058&quot;,&quot;title&quot;:&quot;68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01480973&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01500876&quot;,&quot;title&quot;:&quot;A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01525446&quot;,&quot;title&quot;:&quot;Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02111681&quot;,&quot;title&quot;:&quot;Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01647334&quot;,&quot;title&quot;:&quot;Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01757158&quot;,&quot;title&quot;:&quot;Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01421953&quot;,&quot;title&quot;:&quot;Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01345851&quot;,&quot;title&quot;:&quot;Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01781741&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01946100&quot;,&quot;title&quot;:&quot;Treatment of Multifocal Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02017925&quot;,&quot;title&quot;:&quot;Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02067858&quot;,&quot;title&quot;:&quot;An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM\u2122) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02123888&quot;,&quot;title&quot;:&quot;Simultaneous CBCT Acquisition During Arc Radiotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02130427&quot;,&quot;title&quot;:&quot;A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01108666&quot;,&quot;title&quot;:&quot;Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01167530&quot;,&quot;title&quot;:&quot;Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00264602&quot;,&quot;title&quot;:&quot;Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00846443&quot;,&quot;title&quot;:&quot;Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01899989&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00955942&quot;,&quot;title&quot;:&quot;Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01411098&quot;,&quot;title&quot;:&quot;Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01565772&quot;,&quot;title&quot;:&quot;Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01575782&quot;,&quot;title&quot;:&quot;Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01711697&quot;,&quot;title&quot;:&quot;Standard Radiation Therapy Combined With High Dose, Ablative Radiation in Patients With Advanced Lung Cancer That Cannot be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01933568&quot;,&quot;title&quot;:&quot;Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01958372&quot;,&quot;title&quot;:&quot;Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02059967&quot;,&quot;title&quot;:&quot;Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02172846&quot;,&quot;title&quot;:&quot;Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00351962&quot;,&quot;title&quot;:&quot;Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01102231&quot;,&quot;title&quot;:&quot;Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01636934&quot;,&quot;title&quot;:&quot;Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00379717&quot;,&quot;title&quot;:&quot;Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01755624&quot;,&quot;title&quot;:&quot;Effect of NovoTTF-100A in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391260&quot;,&quot;title&quot;:&quot;Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01503385&quot;,&quot;title&quot;:&quot;Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00452803&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01166204&quot;,&quot;title&quot;:&quot;Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02045446&quot;,&quot;title&quot;:&quot;Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01657799&quot;,&quot;title&quot;:&quot;A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01603849&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01823003&quot;,&quot;title&quot;:&quot;Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00888511&quot;,&quot;title&quot;:&quot;Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01300299&quot;,&quot;title&quot;:&quot;STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00973310&quot;,&quot;title&quot;:&quot;Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01221675&quot;,&quot;title&quot;:&quot;TF2- Small Cell Lung Cancer Radio Immunotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01185639&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00881712&quot;,&quot;title&quot;:&quot;Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01656460&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00875901&quot;,&quot;title&quot;:&quot;Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00938418&quot;,&quot;title&quot;:&quot;Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871454&quot;,&quot;title&quot;:&quot;Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00466089&quot;,&quot;title&quot;:&quot;Study of 3D Radiotherapy With or Without Erlotinib (Tarceva\u00ae) in Patients With Localized Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00591838&quot;,&quot;title&quot;:&quot;A Phase I/II Trial of Stereotactic Body Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00697333&quot;,&quot;title&quot;:&quot;Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00727350&quot;,&quot;title&quot;:&quot;Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00843726&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01024829&quot;,&quot;title&quot;:&quot;Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01029678&quot;,&quot;title&quot;:&quot;Concomitant Radio-chemotherapy in the Elderly&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01051037&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01076231&quot;,&quot;title&quot;:&quot;Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01166191&quot;,&quot;title&quot;:&quot;Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01507428&quot;,&quot;title&quot;:&quot;Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01518621&quot;,&quot;title&quot;:&quot;Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01537991&quot;,&quot;title&quot;:&quot;ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01543672&quot;,&quot;title&quot;:&quot;Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01553916&quot;,&quot;title&quot;:&quot;Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01576796&quot;,&quot;title&quot;:&quot;Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01577212&quot;,&quot;title&quot;:&quot;Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01635270&quot;,&quot;title&quot;:&quot;Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01710956&quot;,&quot;title&quot;:&quot;Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01795521&quot;,&quot;title&quot;:&quot;LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01803542&quot;,&quot;title&quot;:&quot;Stereotactic Radiotherapy (SBRT) of Lung Metastasis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01965223&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy in Lung Metastases From Any Non Haematological Primary Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02002052&quot;,&quot;title&quot;:&quot;Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02014545&quot;,&quot;title&quot;:&quot;Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02058056&quot;,&quot;title&quot;:&quot;Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073968&quot;,&quot;title&quot;:&quot;PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02136355&quot;,&quot;title&quot;:&quot;A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02189967&quot;,&quot;title&quot;:&quot;Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02224547&quot;,&quot;title&quot;:&quot;Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01158170&quot;,&quot;title&quot;:&quot;Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02076477&quot;,&quot;title&quot;:&quot;The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02162537&quot;,&quot;title&quot;:&quot;Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01014130&quot;,&quot;title&quot;:&quot;Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00633568&quot;,&quot;title&quot;:&quot;Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049151&quot;,&quot;title&quot;:&quot;Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01968941&quot;,&quot;title&quot;:&quot;Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01351116&quot;,&quot;title&quot;:&quot;A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01993810&quot;,&quot;title&quot;:&quot;Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01394679&quot;,&quot;title&quot;:&quot;A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00410683&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00632853&quot;,&quot;title&quot;:&quot;Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00880971&quot;,&quot;title&quot;:&quot;To Evaluate Postoperative 3D Conform Radiotherapy in Patients With IIIA (N2) Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00955695&quot;,&quot;title&quot;:&quot;Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01185132&quot;,&quot;title&quot;:&quot;Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459497&quot;,&quot;title&quot;:&quot;Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01780675&quot;,&quot;title&quot;:&quot;Hippocampus Avoidance PCI vs PCI&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">106</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Surgery</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Surgery" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02040662&quot;,&quot;title&quot;:&quot;Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02106143&quot;,&quot;title&quot;:&quot;RejuvenAir\u2122 System Lobectomy Safety and Histology Study&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02206334&quot;,&quot;title&quot;:&quot;Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Surgery" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00425022&quot;,&quot;title&quot;:&quot;VATS Lobectomy for Clinical Stage IB or II Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00862004&quot;,&quot;title&quot;:&quot;Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01054482&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00945451&quot;,&quot;title&quot;:&quot;Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01331863&quot;,&quot;title&quot;:&quot;Airway and/or Pulmonary Vessels Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01533233&quot;,&quot;title&quot;:&quot;Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01847209&quot;,&quot;title&quot;:&quot;Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01941654&quot;,&quot;title&quot;:&quot;ATOM_local Ablative Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Surgery" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00273494&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00499330&quot;,&quot;title&quot;:&quot;Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01053624&quot;,&quot;title&quot;:&quot;Concomitant Tracheostomy and Lung Resection&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01102517&quot;,&quot;title&quot;:&quot;A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01336894&quot;,&quot;title&quot;:&quot;Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01707888&quot;,&quot;title&quot;:&quot;Comparison of Lobectomy and Sublobar Resection for Chinese cT1aN0M0 Peripheral Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02011997&quot;,&quot;title&quot;:&quot;Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Surgery" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01278888&quot;,&quot;title&quot;:&quot;Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01933828&quot;,&quot;title&quot;:&quot;Treatment of Early Stage Lung Cancer by VATS Versus OPEN Lobectomy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01179308&quot;,&quot;title&quot;:&quot;The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01254591&quot;,&quot;title&quot;:&quot;Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00188526&quot;,&quot;title&quot;:&quot;Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00323089&quot;,&quot;title&quot;:&quot;Removal of Lung Nodules After Being Marked With a Microcoil&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01206894&quot;,&quot;title&quot;:&quot;Pre-Operative Assessment of Chest Wall Invasion in NSCLC Using Pre-Operative, Surgeon Performed Ultrasound&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01221493&quot;,&quot;title&quot;:&quot;EBUS Guided Cryo Biopsy of Solitary Pulmonary Nodules&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01236937&quot;,&quot;title&quot;:&quot;Respiration Gated Laser Guided CT Lung Nodule Biopsy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01685580&quot;,&quot;title&quot;:&quot;Non-Invasive Ventilation Preoperative Lung Resection Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01746810&quot;,&quot;title&quot;:&quot;IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01786590&quot;,&quot;title&quot;:&quot;Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01885455&quot;,&quot;title&quot;:&quot;Improving Resection Rates Among African Americans With NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01932489&quot;,&quot;title&quot;:&quot;The Jules Bordet Institute Molecular Profiling Program Feasibility Trial&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01975623&quot;,&quot;title&quot;:&quot;Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02105168&quot;,&quot;title&quot;:&quot;Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02106559&quot;,&quot;title&quot;:&quot;Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;}]">17</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Surgery" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01278888&quot;,&quot;title&quot;:&quot;Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01933828&quot;,&quot;title&quot;:&quot;Treatment of Early Stage Lung Cancer by VATS Versus OPEN Lobectomy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01179308&quot;,&quot;title&quot;:&quot;The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01254591&quot;,&quot;title&quot;:&quot;Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00188526&quot;,&quot;title&quot;:&quot;Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00323089&quot;,&quot;title&quot;:&quot;Removal of Lung Nodules After Being Marked With a Microcoil&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01206894&quot;,&quot;title&quot;:&quot;Pre-Operative Assessment of Chest Wall Invasion in NSCLC Using Pre-Operative, Surgeon Performed Ultrasound&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01221493&quot;,&quot;title&quot;:&quot;EBUS Guided Cryo Biopsy of Solitary Pulmonary Nodules&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01236937&quot;,&quot;title&quot;:&quot;Respiration Gated Laser Guided CT Lung Nodule Biopsy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01685580&quot;,&quot;title&quot;:&quot;Non-Invasive Ventilation Preoperative Lung Resection Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01746810&quot;,&quot;title&quot;:&quot;IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01786590&quot;,&quot;title&quot;:&quot;Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01885455&quot;,&quot;title&quot;:&quot;Improving Resection Rates Among African Americans With NSCLC&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01932489&quot;,&quot;title&quot;:&quot;The Jules Bordet Institute Molecular Profiling Program Feasibility Trial&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01975623&quot;,&quot;title&quot;:&quot;Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02105168&quot;,&quot;title&quot;:&quot;Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02106559&quot;,&quot;title&quot;:&quot;Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02040662&quot;,&quot;title&quot;:&quot;Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02106143&quot;,&quot;title&quot;:&quot;RejuvenAir\u2122 System Lobectomy Safety and Histology Study&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02206334&quot;,&quot;title&quot;:&quot;Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00425022&quot;,&quot;title&quot;:&quot;VATS Lobectomy for Clinical Stage IB or II Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00862004&quot;,&quot;title&quot;:&quot;Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01054482&quot;,&quot;title&quot;:&quot;Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00945451&quot;,&quot;title&quot;:&quot;Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01331863&quot;,&quot;title&quot;:&quot;Airway and/or Pulmonary Vessels Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01533233&quot;,&quot;title&quot;:&quot;Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01847209&quot;,&quot;title&quot;:&quot;Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01941654&quot;,&quot;title&quot;:&quot;ATOM_local Ablative Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00273494&quot;,&quot;title&quot;:&quot;Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00499330&quot;,&quot;title&quot;:&quot;Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01053624&quot;,&quot;title&quot;:&quot;Concomitant Tracheostomy and Lung Resection&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01102517&quot;,&quot;title&quot;:&quot;A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01336894&quot;,&quot;title&quot;:&quot;Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01707888&quot;,&quot;title&quot;:&quot;Comparison of Lobectomy and Sublobar Resection for Chinese cT1aN0M0 Peripheral Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02011997&quot;,&quot;title&quot;:&quot;Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">35</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Other interventions</td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Acupuncture</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01408212&quot;,&quot;title&quot;:&quot;Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01408212&quot;,&quot;title&quot;:&quot;Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Acetylsalicylic acid</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Acetylsalicylic acid" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acetylsalicylic acid" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acetylsalicylic acid" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acetylsalicylic acid" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01707823&quot;,&quot;title&quot;:&quot;Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acetylsalicylic acid" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01707823&quot;,&quot;title&quot;:&quot;Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ADI-PEG 20</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="ADI-PEG 20" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497925&quot;,&quot;title&quot;:&quot;Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02029690&quot;,&quot;title&quot;:&quot;Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="ADI-PEG 20" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ADI-PEG 20" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="ADI-PEG 20" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="ADI-PEG 20" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497925&quot;,&quot;title&quot;:&quot;Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02029690&quot;,&quot;title&quot;:&quot;Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Anvirzel</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Anvirzel" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01562301&quot;,&quot;title&quot;:&quot;Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Anvirzel" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anvirzel" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Anvirzel" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Anvirzel" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01562301&quot;,&quot;title&quot;:&quot;Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Arsenic trioxide</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Arsenic trioxide" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02066870&quot;,&quot;title&quot;:&quot;Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Arsenic trioxide" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01470248&quot;,&quot;title&quot;:&quot;Study of Arsenic Trioxide in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Arsenic trioxide" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Arsenic trioxide" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Arsenic trioxide" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02066870&quot;,&quot;title&quot;:&quot;Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01470248&quot;,&quot;title&quot;:&quot;Study of Arsenic Trioxide in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Astagalus-based formula: qingshu-yiqi-tang</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Astagalus-based formula: qingshu-yiqi-tang" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Astagalus-based formula: qingshu-yiqi-tang" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Astagalus-based formula: qingshu-yiqi-tang" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01802021&quot;,&quot;title&quot;:&quot;Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Astagalus-based formula: qingshu-yiqi-tang" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Astagalus-based formula: qingshu-yiqi-tang" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01802021&quot;,&quot;title&quot;:&quot;Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Auranofin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Beta-glucan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Beta-glucan" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Beta-glucan" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Beta-glucan" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Beta-glucan" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00682032&quot;,&quot;title&quot;:&quot;The Effect of Beta-glucan in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Beta-glucan" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00682032&quot;,&quot;title&quot;:&quot;The Effect of Beta-glucan in Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Celecoxib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Celecoxib" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Celecoxib" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01503385&quot;,&quot;title&quot;:&quot;Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00520845&quot;,&quot;title&quot;:&quot;Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Celecoxib" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Celecoxib" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Celecoxib" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01503385&quot;,&quot;title&quot;:&quot;Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00520845&quot;,&quot;title&quot;:&quot;Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Clusterin i</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Clusterin i" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Clusterin i" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Clusterin i" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01630733&quot;,&quot;title&quot;:&quot;A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Clusterin i" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Clusterin i" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01630733&quot;,&quot;title&quot;:&quot;A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">dotap:chol-fus1 (FUS1-nanoparticles)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="dotap:chol-fus1 (FUS1-nanoparticles)" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="dotap:chol-fus1 (FUS1-nanoparticles)" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01455389&quot;,&quot;title&quot;:&quot;FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="dotap:chol-fus1 (FUS1-nanoparticles)" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="dotap:chol-fus1 (FUS1-nanoparticles)" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="dotap:chol-fus1 (FUS1-nanoparticles)" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01455389&quot;,&quot;title&quot;:&quot;FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Early preventative, palliative care</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Early preventative, palliative care" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02237183&quot;,&quot;title&quot;:&quot;Iloprost in Preventing Lung Cancer in Former Smokers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Early preventative, palliative care" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Early preventative, palliative care" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01401907&quot;,&quot;title&quot;:&quot;Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Early preventative, palliative care" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Early preventative, palliative care" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02237183&quot;,&quot;title&quot;:&quot;Iloprost in Preventing Lung Cancer in Former Smokers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01401907&quot;,&quot;title&quot;:&quot;Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">EC1456</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="EC1456" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999738&quot;,&quot;title&quot;:&quot;Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="EC1456" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="EC1456" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="EC1456" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EC1456" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999738&quot;,&quot;title&quot;:&quot;Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ethaselen</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ethaselen" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02166242&quot;,&quot;title&quot;:&quot;Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ethaselen" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ethaselen" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ethaselen" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ethaselen" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02166242&quot;,&quot;title&quot;:&quot;Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Endostar</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Endostar" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostar" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01669707&quot;,&quot;title&quot;:&quot;Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01549093&quot;,&quot;title&quot;:&quot;Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01564329&quot;,&quot;title&quot;:&quot;The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01158144&quot;,&quot;title&quot;:&quot;Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostar" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00576914&quot;,&quot;title&quot;:&quot;Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostar" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00813332&quot;,&quot;title&quot;:&quot;Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01028729&quot;,&quot;title&quot;:&quot;A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostar" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00813332&quot;,&quot;title&quot;:&quot;Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01028729&quot;,&quot;title&quot;:&quot;A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01669707&quot;,&quot;title&quot;:&quot;Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01549093&quot;,&quot;title&quot;:&quot;Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01564329&quot;,&quot;title&quot;:&quot;The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01158144&quot;,&quot;title&quot;:&quot;Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00576914&quot;,&quot;title&quot;:&quot;Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Endostatins, stantins, pagylated endostatins</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Endostatins, stantins, pagylated endostatins" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostatins, stantins, pagylated endostatins" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01192230&quot;,&quot;title&quot;:&quot;Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01733589&quot;,&quot;title&quot;:&quot;Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005120&quot;,&quot;title&quot;:&quot;Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01527864&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td data-content-name="lung-cancer" data-intervention="Endostatins, stantins, pagylated endostatins" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Endostatins, stantins, pagylated endostatins" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Endostatins, stantins, pagylated endostatins" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01192230&quot;,&quot;title&quot;:&quot;Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01156545&quot;,&quot;title&quot;:&quot;BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01733589&quot;,&quot;title&quot;:&quot;Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005120&quot;,&quot;title&quot;:&quot;Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01527864&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Enoxaparin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Enoxaparin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Enoxaparin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Enoxaparin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00717938&quot;,&quot;title&quot;:&quot;A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Enoxaparin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Enoxaparin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00717938&quot;,&quot;title&quot;:&quot;A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Finasteride</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Finasteride" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Finasteride" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02055170&quot;,&quot;title&quot;:&quot;Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Finasteride" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Finasteride" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Finasteride" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02055170&quot;,&quot;title&quot;:&quot;Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Fulvestrant</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Fulvestrant" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Fulvestrant" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Fulvestrant" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Fulvestrant" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Fulvestrant" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01556191&quot;,&quot;title&quot;:&quot;Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Gossypol</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Gossypol" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Gossypol" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gossypol" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01977209&quot;,&quot;title&quot;:&quot;Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Gossypol" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gossypol" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01977209&quot;,&quot;title&quot;:&quot;Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Hydroxychloroquine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Hydroxychloroquine" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hydroxychloroquine" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00809237&quot;,&quot;title&quot;:&quot;Hydroxychloroquine and Gefitinib to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Hydroxychloroquine" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Hydroxychloroquine" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hydroxychloroquine" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00809237&quot;,&quot;title&quot;:&quot;Hydroxychloroquine and Gefitinib to Treat Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Inhaled Vidaza</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Inhaled Vidaza" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02009436&quot;,&quot;title&quot;:&quot;A Study of Inhaled Vidaza in Advanced Non-Small Cell Lung Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Inhaled Vidaza" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Inhaled Vidaza" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Inhaled Vidaza" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Inhaled Vidaza" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02009436&quot;,&quot;title&quot;:&quot;A Study of Inhaled Vidaza in Advanced Non-Small Cell Lung Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Ketogenic diet</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Ketogenic diet" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01419587&quot;,&quot;title&quot;:&quot;Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ketogenic diet" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ketogenic diet" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ketogenic diet" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ketogenic diet" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01419587&quot;,&quot;title&quot;:&quot;Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">KML-001</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="KML-001" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01110226&quot;,&quot;title&quot;:&quot;Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="KML-001" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="KML-001" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="KML-001" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="KML-001" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01110226&quot;,&quot;title&quot;:&quot;Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Melatonin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Melatonin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Melatonin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Melatonin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00668707&quot;,&quot;title&quot;:&quot;Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Melatonin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Melatonin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00668707&quot;,&quot;title&quot;:&quot;Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Metformin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Metformin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Metformin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01997775&quot;,&quot;title&quot;:&quot;Metformin in Stage IV Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864681&quot;,&quot;title&quot;:&quot;Combination of Metformin With Gefitinib to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02019979&quot;,&quot;title&quot;:&quot;Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy in Stage IV NS-NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115464&quot;,&quot;title&quot;:&quot;Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01717482&quot;,&quot;title&quot;:&quot;Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186847&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td><td data-content-name="lung-cancer" data-intervention="Metformin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Metformin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Metformin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01997775&quot;,&quot;title&quot;:&quot;Metformin in Stage IV Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864681&quot;,&quot;title&quot;:&quot;Combination of Metformin With Gefitinib to Treat NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02019979&quot;,&quot;title&quot;:&quot;Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy in Stage IV NS-NSCLC&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115464&quot;,&quot;title&quot;:&quot;Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01717482&quot;,&quot;title&quot;:&quot;Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02186847&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Mindfulness</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01494883&quot;,&quot;title&quot;:&quot;Mindfulness for Lung Cancer Patients and Partners&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01494883&quot;,&quot;title&quot;:&quot;Mindfulness for Lung Cancer Patients and Partners&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Mithramycin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01624090&quot;,&quot;title&quot;:&quot;Mithramycin for Lung, Esophagus, and Other Chest Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01624090&quot;,&quot;title&quot;:&quot;Mithramycin for Lung, Esophagus, and Other Chest Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nelfinavir</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Nelfinavir" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nelfinavir" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00589056&quot;,&quot;title&quot;:&quot;Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Nelfinavir" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nelfinavir" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nelfinavir" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00589056&quot;,&quot;title&quot;:&quot;Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nitroglycerin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Nitroglycerin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nitroglycerin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01210378&quot;,&quot;title&quot;:&quot;Nitroglycerin in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01171170&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Nitroglycerin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nitroglycerin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nitroglycerin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01210378&quot;,&quot;title&quot;:&quot;Nitroglycerin in Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01171170&quot;,&quot;title&quot;:&quot;Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">NSAID</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="NSAID" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="NSAID" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="NSAID" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01058902&quot;,&quot;title&quot;:&quot;The Effect Of Aspirin On Survival in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="NSAID" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="NSAID" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01058902&quot;,&quot;title&quot;:&quot;The Effect Of Aspirin On Survival in Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PLX7486</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PLX7486" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01804530&quot;,&quot;title&quot;:&quot;Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PLX7486" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PLX7486" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PLX7486" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PLX7486" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01804530&quot;,&quot;title&quot;:&quot;Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Photodynamic Therapy</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Photodynamic Therapy" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01854684&quot;,&quot;title&quot;:&quot;Photodynamic Therapy During Surgery in Treating Patients With Non-Small Cell Lung Cancer That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Photodynamic Therapy" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00601848&quot;,&quot;title&quot;:&quot;Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Photodynamic Therapy" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Photodynamic Therapy" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00754910&quot;,&quot;title&quot;:&quot;Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Photodynamic Therapy" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00754910&quot;,&quot;title&quot;:&quot;Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01854684&quot;,&quot;title&quot;:&quot;Photodynamic Therapy During Surgery in Treating Patients With Non-Small Cell Lung Cancer That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00601848&quot;,&quot;title&quot;:&quot;Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Reolysin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Reolysin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Reolysin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01708993&quot;,&quot;title&quot;:&quot;Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Reolysin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Reolysin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Reolysin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01708993&quot;,&quot;title&quot;:&quot;Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Retinoic Acid</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Retinoic Acid" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Retinoic Acid" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Retinoic Acid" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01041833&quot;,&quot;title&quot;:&quot;Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Retinoic Acid" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Retinoic Acid" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01041833&quot;,&quot;title&quot;:&quot;Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Silybin-phytosome</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Silybin-phytosome" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Silybin-phytosome" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02146118&quot;,&quot;title&quot;:&quot;A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Silybin-phytosome" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Silybin-phytosome" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Silybin-phytosome" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02146118&quot;,&quot;title&quot;:&quot;A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Talactoferrin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Talactoferrin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Talactoferrin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Talactoferrin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00706862&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Talactoferrin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Talactoferrin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00706862&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tetrathiomolybdate</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Tetrathiomolybdate" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01837329&quot;,&quot;title&quot;:&quot;Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tetrathiomolybdate" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tetrathiomolybdate" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tetrathiomolybdate" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tetrathiomolybdate" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01837329&quot;,&quot;title&quot;:&quot;Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">TH-302</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="TH-302" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="TH-302" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02093962&quot;,&quot;title&quot;:&quot;Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="TH-302" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="TH-302" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="TH-302" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02093962&quot;,&quot;title&quot;:&quot;Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tinzaparin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Tinzaparin" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Tinzaparin" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tinzaparin" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00475098&quot;,&quot;title&quot;:&quot;Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Tinzaparin" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Tinzaparin" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00475098&quot;,&quot;title&quot;:&quot;Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Valproic acid</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Valproic acid" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Valproic acid" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01203735&quot;,&quot;title&quot;:&quot;Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Valproic acid" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Valproic acid" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Valproic acid" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01203735&quot;,&quot;title&quot;:&quot;Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Vegetable + herb mix</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Vegetable + herb mix" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vegetable + herb mix" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vegetable + herb mix" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00246727&quot;,&quot;title&quot;:&quot;Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vegetable + herb mix" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02195453&quot;,&quot;title&quot;:&quot;Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vegetable + herb mix" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02195453&quot;,&quot;title&quot;:&quot;Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00246727&quot;,&quot;title&quot;:&quot;Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Vitamin D/Calcitriol</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Vitamin D/Calcitriol" data-phase="phase1" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00690924&quot;,&quot;title&quot;:&quot;Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01631526&quot;,&quot;title&quot;:&quot;Vitamin D Loading Dose in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01820299&quot;,&quot;title&quot;:&quot;Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Vitamin D/Calcitriol" data-phase="phase2" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vitamin D/Calcitriol" data-phase="phase3" data-placement="bottom" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Vitamin D/Calcitriol" data-phase="other" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Vitamin D/Calcitriol" data-phase="all" data-placement="bottom_left" data-popup-id="non-small-cell-lung-cancer-nsclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00690924&quot;,&quot;title&quot;:&quot;Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01631526&quot;,&quot;title&quot;:&quot;Vitamin D Loading Dose in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01820299&quot;,&quot;title&quot;:&quot;Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td></div></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The+Non-Small+Cell+Lung+Cancer+trial+table+is+missing+a+trial&trial_table=Non-Small+Cell+Lung+Cancer.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='non-small-cell-lung-cancer-nsclc'></div>
</div><div class="trial_table small-cell-lung-cancer_table hide"><table class='small-cell-lung-cancer-sclc' data-condition-name='Small Cell Lung Cancer' id='trial-widget'>
<tr>
<th>
<div class='condition_name'>
Small Cell Lung Cancer
</div>
</th>
<th>
<div class='big'>
11
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
45
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
8
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
5
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
69
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">Targeted Therapies</td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="EGFR" data-id="small-cell-lung-cancer-sclc" data-name="egfr_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">EGFR</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="EGFR" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="EGFR" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="EGFR" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="egfr_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Erlotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Erlotinib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="MEK" data-id="small-cell-lung-cancer-sclc" data-name="mek_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEK</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MEK" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MEK" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MEK" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="mek_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AZD6244</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01605916&quot;,&quot;title&quot;:&quot;Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="AZD6244" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="VEGF" data-id="small-cell-lung-cancer-sclc" data-name="vegf_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VEGF</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00755157&quot;,&quot;title&quot;:&quot;Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01441297&quot;,&quot;title&quot;:&quot;BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="VEGF" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="VEGF" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="VEGF" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00755157&quot;,&quot;title&quot;:&quot;Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01441297&quot;,&quot;title&quot;:&quot;BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bevacizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00755157&quot;,&quot;title&quot;:&quot;Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bevacizumab" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="vegf_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nintedanib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01441297&quot;,&quot;title&quot;:&quot;BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Nintedanib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PI3K (PI3K/AKT)" data-id="small-cell-lung-cancer-sclc" data-name="pi3k-pi3k-akt_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PI3K (PI3K/AKT)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02194049&quot;,&quot;title&quot;:&quot;Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PI3K (PI3K/AKT)" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02194049&quot;,&quot;title&quot;:&quot;Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Buparlisib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02194049&quot;,&quot;title&quot;:&quot;Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Buparlisib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="pi3k-pi3k-akt_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MK-2206</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="MK-2206" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Multi kinase inhibitors" data-id="small-cell-lung-cancer-sclc" data-name="multi-kinase-inhibitors_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Multi kinase inhibitors</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01713296&quot;,&quot;title&quot;:&quot;Pazopanib in Relapsed and Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Multi kinase inhibitors" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01713296&quot;,&quot;title&quot;:&quot;Pazopanib in Relapsed and Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Lapatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Lapatinib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pazopanib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01713296&quot;,&quot;title&quot;:&quot;Pazopanib in Relapsed and Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Pazopanib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multi-kinase-inhibitors_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sunitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01306045&quot;,&quot;title&quot;:&quot;Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sunitinib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Proteasome" data-id="small-cell-lung-cancer-sclc" data-name="proteasome_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Proteasome</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987232&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Proteasome" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987232&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="proteasome_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Carfilzomib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01941316&quot;,&quot;title&quot;:&quot;Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987232&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Carfilzomib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Hedgehog" data-id="small-cell-lung-cancer-sclc" data-name="hedgehog_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Hedgehog</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Hedgehog" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579929&quot;,&quot;title&quot;:&quot;Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hedgehog" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01722292&quot;,&quot;title&quot;:&quot;A Study of LY2940680 in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Hedgehog" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Hedgehog" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Hedgehog" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579929&quot;,&quot;title&quot;:&quot;Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01722292&quot;,&quot;title&quot;:&quot;A Study of LY2940680 in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="hedgehog_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LDE225</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="LDE225" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01579929&quot;,&quot;title&quot;:&quot;Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LDE225" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDE225" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDE225" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LDE225" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="hedgehog_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LY2940680</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="LY2940680" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="LY2940680" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01722292&quot;,&quot;title&quot;:&quot;A Study of LY2940680 in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="LY2940680" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2940680" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="LY2940680" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="FYN3" data-id="small-cell-lung-cancer-sclc" data-name="fyn3_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">FYN3</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="FYN3" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="FYN3" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01901653&quot;,&quot;title&quot;:&quot;SC16LD6.5 in Recurrent Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="FYN3" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="FYN3" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="FYN3" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01901653&quot;,&quot;title&quot;:&quot;SC16LD6.5 in Recurrent Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="fyn3_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">SC16LD6.5</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="SC16LD6.5" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="SC16LD6.5" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01901653&quot;,&quot;title&quot;:&quot;SC16LD6.5 in Recurrent Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="SC16LD6.5" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="SC16LD6.5" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="SC16LD6.5" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CDK" data-id="small-cell-lung-cancer-sclc" data-name="cdk_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CDK</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="CDK" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01573338&quot;,&quot;title&quot;:&quot;Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02161419&quot;,&quot;title&quot;:&quot;RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="CDK" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CDK" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CDK" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01573338&quot;,&quot;title&quot;:&quot;Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02161419&quot;,&quot;title&quot;:&quot;RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="cdk_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Roniciclib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Roniciclib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Roniciclib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01573338&quot;,&quot;title&quot;:&quot;Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02161419&quot;,&quot;title&quot;:&quot;RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Roniciclib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Roniciclib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Roniciclib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="BCR-ABL" data-id="small-cell-lung-cancer-sclc" data-name="bcr-abl_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BCR-ABL</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="BCR-ABL" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="bcr-abl_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ponatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01935336&quot;,&quot;title&quot;:&quot;Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ponatinib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="mTOR" data-id="small-cell-lung-cancer-sclc" data-name="mtor_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">mTOR</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="mTOR" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="mTOR" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="mTOR" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="mtor_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sirolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Sirolimus" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CTLA-4" data-id="small-cell-lung-cancer-sclc" data-name="ctla-4_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CTLA-4</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02046733&quot;,&quot;title&quot;:&quot;Small Cell Lung Cancer Trial With IpiliMUmab in LImited Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CTLA-4" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02046733&quot;,&quot;title&quot;:&quot;Small Cell Lung Cancer Trial With IpiliMUmab in LImited Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="ctla-4_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ipilimumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02046733&quot;,&quot;title&quot;:&quot;Small Cell Lung Cancer Trial With IpiliMUmab in LImited Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Ipilimumab" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PARP" data-id="small-cell-lung-cancer-sclc" data-name="parp_targeted-therapies"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PARP</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01638546&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01642251&quot;,&quot;title&quot;:&quot;Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="PARP" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="PARP" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="PARP" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01638546&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01642251&quot;,&quot;title&quot;:&quot;Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="parp_targeted-therapies hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Veliparib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01638546&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01642251&quot;,&quot;title&quot;:&quot;Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Veliparib" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="null">2</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Vaccines</td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Autologous tumor cell vaccine + ISCOMATRIX adjuvant</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01258868&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous tumor cell vaccine + ISCOMATRIX adjuvant" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01258868&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">H1299 cell lysate</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="H1299 cell lysate" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">HLA-A*2402-restricted CDCA1 and KIF20A peptides</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*2402-restricted CDCA1 and KIF20A peptides" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069653&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="HLA-A*2402-restricted CDCA1 and KIF20A peptides" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HLA-A*2402-restricted CDCA1 and KIF20A peptides" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="HLA-A*2402-restricted CDCA1 and KIF20A peptides" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="HLA-A*2402-restricted CDCA1 and KIF20A peptides" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01069653&quot;,&quot;title&quot;:&quot;Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Chemotherapy</td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cisplatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cisplatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cisplatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cisplatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01487499&quot;,&quot;title&quot;:&quot;Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cisplatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cisplatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01487499&quot;,&quot;title&quot;:&quot;Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bendamustin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Bendamustin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bendamustin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168922&quot;,&quot;title&quot;:&quot;Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Bendamustin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Bendamustin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Bendamustin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168922&quot;,&quot;title&quot;:&quot;Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Carboplatin + Irinotecan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Carboplatin + Irinotecan" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Carboplatin + Irinotecan" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carboplatin + Irinotecan" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168896&quot;,&quot;title&quot;:&quot;A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Carboplatin + Irinotecan" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carboplatin + Irinotecan" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168896&quot;,&quot;title&quot;:&quot;A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Irinotecan + Cisplatin + Simvastatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin + Simvastatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin + Simvastatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01441349&quot;,&quot;title&quot;:&quot;Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin + Simvastatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin + Simvastatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin + Simvastatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01441349&quot;,&quot;title&quot;:&quot;Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Irinotecan + Cisplatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02171325&quot;,&quot;title&quot;:&quot;Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Irinotecan + Cisplatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02171325&quot;,&quot;title&quot;:&quot;Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Carboplatin + Etoposide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Carboplatin + Etoposide" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carboplatin + Etoposide" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carboplatin + Etoposide" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00168896&quot;,&quot;title&quot;:&quot;A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Carboplatin + Etoposide" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Carboplatin + Etoposide" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00168896&quot;,&quot;title&quot;:&quot;A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Belotecan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Belotecan" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Belotecan" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497873&quot;,&quot;title&quot;:&quot;Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Belotecan" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00826644&quot;,&quot;title&quot;:&quot;Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Belotecan" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Belotecan" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497873&quot;,&quot;title&quot;:&quot;Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00826644&quot;,&quot;title&quot;:&quot;Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Topotecan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Topotecan" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Topotecan" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497873&quot;,&quot;title&quot;:&quot;Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01417806&quot;,&quot;title&quot;:&quot;Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Topotecan" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Topotecan" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Topotecan" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01497873&quot;,&quot;title&quot;:&quot;Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01417806&quot;,&quot;title&quot;:&quot;Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Temozolomide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Temozolomide" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Temozolomide" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01900951&quot;,&quot;title&quot;:&quot;Temozolomide as Maintenance Therapy in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01638546&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="lung-cancer" data-intervention="Temozolomide" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Temozolomide" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Temozolomide" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01900951&quot;,&quot;title&quot;:&quot;Temozolomide as Maintenance Therapy in Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01638546&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Docetaxel + Carboplatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Docetaxel + Carboplatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Docetaxel + Carboplatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00686985&quot;,&quot;title&quot;:&quot;Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Docetaxel + Carboplatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Docetaxel + Carboplatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Docetaxel + Carboplatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00686985&quot;,&quot;title&quot;:&quot;Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Gemcitabine + Pemetrexed + Cisplatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Gemcitabine + Pemetrexed + Cisplatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Gemcitabine + Pemetrexed + Cisplatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gemcitabine + Pemetrexed + Cisplatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01656551&quot;,&quot;title&quot;:&quot;Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Gemcitabine + Pemetrexed + Cisplatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Gemcitabine + Pemetrexed + Cisplatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01656551&quot;,&quot;title&quot;:&quot;Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Etirinotecan</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Etirinotecan" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Etirinotecan" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01876446&quot;,&quot;title&quot;:&quot;Etirinotecan Pegol (NKTR 102) in Treating Patients With Relapsed Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Etirinotecan" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Etirinotecan" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Etirinotecan" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01876446&quot;,&quot;title&quot;:&quot;Etirinotecan Pegol (NKTR 102) in Treating Patients With Relapsed Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cisplatin + Etoposide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Cisplatin + Etoposide" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cisplatin + Etoposide" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cisplatin + Etoposide" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00526396&quot;,&quot;title&quot;:&quot;STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cisplatin + Etoposide" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cisplatin + Etoposide" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00526396&quot;,&quot;title&quot;:&quot;STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Belotecan + Cisplatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Belotecan + Cisplatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Belotecan + Cisplatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00754858&quot;,&quot;title&quot;:&quot;Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Belotecan + Cisplatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Belotecan + Cisplatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Belotecan + Cisplatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00754858&quot;,&quot;title&quot;:&quot;Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Radiation Therapy</td></tr><tr class=""><td><div><img alt="radiation" height="24" src="../assets/icon-radiation-2142d7789fc4a2dc44afd5eaa933d211.png" width="24" /><span class="intervention">Radiation</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01426841&quot;,&quot;title&quot;:&quot;Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01745445&quot;,&quot;title&quot;:&quot;Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797159&quot;,&quot;title&quot;:&quot;Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01055197&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02041845&quot;,&quot;title&quot;:&quot;Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02030184&quot;,&quot;title&quot;:&quot;Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01731548&quot;,&quot;title&quot;:&quot;A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01982123&quot;,&quot;title&quot;:&quot;SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01757158&quot;,&quot;title&quot;:&quot;Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Radiation" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01982123&quot;,&quot;title&quot;:&quot;SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01757158&quot;,&quot;title&quot;:&quot;Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01426841&quot;,&quot;title&quot;:&quot;Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01745445&quot;,&quot;title&quot;:&quot;Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01797159&quot;,&quot;title&quot;:&quot;Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01055197&quot;,&quot;title&quot;:&quot;Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02041845&quot;,&quot;title&quot;:&quot;Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02030184&quot;,&quot;title&quot;:&quot;Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01731548&quot;,&quot;title&quot;:&quot;A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">10</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Other Interventions</td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Acupuncture</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01408212&quot;,&quot;title&quot;:&quot;Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Acupuncture" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01408212&quot;,&quot;title&quot;:&quot;Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Auranofin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Auranofin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01737502&quot;,&quot;title&quot;:&quot;PKCi \u0026 mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous cytokine-induced killer cells</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Autologous cytokine-induced killer cells" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous cytokine-induced killer cells" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01592422&quot;,&quot;title&quot;:&quot;Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Autologous cytokine-induced killer cells" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Autologous cytokine-induced killer cells" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Autologous cytokine-induced killer cells" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01592422&quot;,&quot;title&quot;:&quot;Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Chloroquine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Chloroquine" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00969306&quot;,&quot;title&quot;:&quot;Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Chloroquine" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Chloroquine" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Chloroquine" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Chloroquine" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00969306&quot;,&quot;title&quot;:&quot;Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cilengitide</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Cilengitide" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00884598&quot;,&quot;title&quot;:&quot;Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CPI-613</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="CPI-613" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CPI-613" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="CPI-613" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CPI-613" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01931787&quot;,&quot;title&quot;:&quot;CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="CPI-613" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01931787&quot;,&quot;title&quot;:&quot;CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Desipramine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Desipramine" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Desipramine" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01719861&quot;,&quot;title&quot;:&quot;Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Desipramine" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Desipramine" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Desipramine" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01719861&quot;,&quot;title&quot;:&quot;Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Early palliative care</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Early palliative care" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Early palliative care" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Early palliative care" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01401907&quot;,&quot;title&quot;:&quot;Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Early palliative care" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Early palliative care" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01401907&quot;,&quot;title&quot;:&quot;Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">GSK2879552</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK2879552" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02034123&quot;,&quot;title&quot;:&quot;Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="GSK2879552" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK2879552" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="GSK2879552" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="GSK2879552" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02034123&quot;,&quot;title&quot;:&quot;Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Mindfulness</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01494883&quot;,&quot;title&quot;:&quot;Mindfulness for Lung Cancer Patients and Partners&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mindfulness" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01494883&quot;,&quot;title&quot;:&quot;Mindfulness for Lung Cancer Patients and Partners&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Mithramycin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01624090&quot;,&quot;title&quot;:&quot;Mithramycin for Lung, Esophagus, and Other Chest Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Mithramycin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01624090&quot;,&quot;title&quot;:&quot;Mithramycin for Lung, Esophagus, and Other Chest Cancers&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="supplement" height="24" src="../assets/icon-supplement-a7b1b1d2ed8cb3e138529cdef4547bc3.png" width="24" /><span class="intervention">Oral green tea extract</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="lung-cancer" data-intervention="Oral green tea extract" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01317953&quot;,&quot;title&quot;:&quot;Oral Green Tea Extract for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Oral green tea extract" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Oral green tea extract" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Oral green tea extract" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Oral green tea extract" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01317953&quot;,&quot;title&quot;:&quot;Oral Green Tea Extract for Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pasireotide</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Pasireotide" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pasireotide" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01417806&quot;,&quot;title&quot;:&quot;Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Pasireotide" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Pasireotide" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Pasireotide" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01417806&quot;,&quot;title&quot;:&quot;Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Selinexor</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Selinexor" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Selinexor" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02213133&quot;,&quot;title&quot;:&quot;Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Selinexor" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Selinexor" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Selinexor" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02213133&quot;,&quot;title&quot;:&quot;Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Simvastatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="lung-cancer" data-intervention="Simvastatin" data-phase="phase1" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Simvastatin" data-phase="phase2" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01441349&quot;,&quot;title&quot;:&quot;Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="lung-cancer" data-intervention="Simvastatin" data-phase="phase3" data-placement="bottom" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td data-content-name="lung-cancer" data-intervention="Simvastatin" data-phase="other" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="lung-cancer" data-intervention="Simvastatin" data-phase="all" data-placement="bottom_left" data-popup-id="small-cell-lung-cancer-sclc" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01441349&quot;,&quot;title&quot;:&quot;Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The+Small+Cell+Lung+Cancer+trial+table+is+missing+a+trial&trial_table=Small+Cell+Lung+Cancer.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='small-cell-lung-cancer-sclc'></div>
</div></div>
</div>
</div>

</div>
<div class='span3 sidebar no-padding-or-margin'>

<div class='widget '>
<div class='community-promo'>
<h1><a href="../communities/lung-cancer.html">Lung Cancer at Smart Patients</a></h1>
<p>
The Smart Patients lung cancer community, where patients and caregivers affected by lung cancer learn from each other.
</p>
</div>

<hr>
</div>
<div class='widget '>
<div class='invitation-widget'>
<h2>Join the conversation!</h2>
<form accept-charset="UTF-8" action="/users" class="signup form-inline" id="new_user" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" /></div><div class='join-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class="control-group required"><div class="controls"><input class="email required ezpz" id="invitation_email" name="user[email]" placeholder="Enter your email address" required="required" size="30" type="text" /></div></div>
<div class="notice"><p>If you're not a patient or caregiver, <a href="../contact-subject=Joining+Smart+Patients.html">click here</a>.</p></div>
<div class='notice'>
<p class='already-a-member'>Already a member? <a href="../signin.html">Sign in</a>.</p>
</div>
<input id="community" name="community" type="hidden" value="lung-cancer" />
<input id="partner" name="partner" type="hidden" value="" />
<input id="tags" name="tags" type="hidden" value="lung cancer" />
<input id="return_url" name="return_url" type="hidden" value="/lung-cancer/trials" />
<div class='controls request-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class='clearfix'></div>
</form>
</div>


<hr>
</div>
<div class='widget '>
<p>The patient handbook from The Bonnie J. Addario Lung Cancer Foundation, "Navigating Lung Cancer, 360 Degrees of Hope," is packed with valuable information. You can download it <a href="http://www.lungcancerfoundation.org/patients/newly-diagnosed" target="_blank">here</a>.</p>
<figure>
<img alt="CFTR mutations" height="165" src="../assets/content_pages/lung-cancer-handbook-740aede5886c6510275686fc70fb519b.png" width="160" />
<figcaption></figcaption>
</figure>

<hr>
</div>


</div>
</div>
</div>
</div>
</div>
<div class='footer_background_container'>
<div class='footer_background'></div>
</div>
<div id='fat_footer'>
<div class='container'>
<footer class='row'>
<ul>
<li class='title'>
Links
</li>
<li>
<a href='../signin.html' title='Smart Patients - Home'>Conversations</a>
</li>
<li>
<a href='../stories.html' title='Stories'>Stories</a>
</li>
<li>
<a href='../quotes.html' title='Quotes recommended by members of the Smart Patients community.'>Quotes</a>
</li>
<li>
<a href='../trials.html' title='Search for clinical trials'>Clinical Trials</a>
</li>
</ul>
<ul>
<li class='title'>
Resources
</li>
<li>
<a href='../tutorial.html' title='Tutorial'>Tutorial</a>
</li>
<li>
<a href='../glossary.html' title='Tutorial'>Glossary</a>
</li>
<li>
<a href='../faq.html' title='Frequently asked questions'>FAQ</a>
</li>
</ul>
<ul>
<li class='title'>
Company
</li>
<li>
<a href='../about.html' title='About'>About</a>
</li>
<li>
<a href='../terms.html' title='Terms of Agreement'>Terms</a>
</li>
<li>
<a href='../privacy.html' title='Privacy Statement'>Privacy</a>
</li>
<li>
<a href='../contact.html' title='Contact Us'>Contact Us</a>
</li>
</ul>
<ul>
<li class='title'>
Social
</li>
<li>
<a href='../voices.html' title='Community Voices'>
<img alt="Icon_community_voices" src="../assets/icon_community_voices-51b928126bf735b2f04e9c969184afe3.png" />
Community Voices
</a>
</li>
<li>
<a href='../blog/index.html' title='Smart Patients Blog'>
<img alt="Icon_rss" src="../assets/icon_rss-16f5922fc759195730036b4454ef43a9.png" />
Smart Patients Blog
</a>
</li>
<li>
<a href='https://twitter.com/smart_patients' target='_blank' title='Twitter'>
<img alt="Icon_twitter" src="../assets/icon_twitter-5f7dbcc5d175199272b25b76fdda7dcd.png" />
Twitter
</a>
</li>
<li>
<a href='https://www.facebook.com/pages/Smart-Patients/393175704082838' target='_blank' title='Facebook'>
<img alt="Icon_facebook" src="../assets/icon_facebook-bb0ca36aa4757152d61004e0595d2e50.png" />
Facebook
</a>
</li>
</ul>
</footer>
<div class='copyright'>&copy;2015 Smart Patients, Inc., all rights reserved
</div>
<div class='creative_commons'>
<a href="../creative_commons.html">some icons</a>
are licensed under the Creative Commons license.
</div>
</div>
</div>

<script>
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', "UA-33347034-1"]);
  _gaq.push(['_setDomainName', 'smartpatients.com']);
  _gaq.push(['_trackPageview']);
  
  _gaq.push(['_setCustomVar',
    1,
    'logged_in',
    "false",
    2 // session-level
  ]);
  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>


<script src="../assets/application-6488ad0d66b77f64bcc10cde7b8e3212.js" type="text/javascript"></script>
<script src="../assets/jquery.hoverIntent.minified-3948fb0a36bb799e79553266985a1b22.js" type="text/javascript"></script>
<script src="../assets/jquery.validate.min-639617c1797dd4f18f2e40348e222928.js" type="text/javascript"></script>
<script src="../assets/jquery.cookie-108e498e814a1dbb62f1c6a88c61db48.js" type="text/javascript"></script>
<!--[if lt IE 10]>  <![endif]-->
<script src="../assets/jquery.placeholder.min-635ef1b648831ce3225097bb831210ca.js" type="text/javascript"></script>
<script>
  (function() {
    var root;
  
    root = typeof exports !== "undefined" && exports !== null ? exports : this;
  
    if ($('.wmd-input').length === 1) {
      root.converter = Markdown.getSanitizingConverter();
      root.converter.hooks.chain("preConversion", function(text) {
        text = text.replace(/^https?:\/\/[a-z0-9\.:]+(\/forums\/1-conversations\/topics\/[0-9]+-.*$)/mgi, "[Title of linked conversation will appear here]($1)");
        text = text.replace(/^(NCT[0-9]{8})$/mgi, "[Title for '$1' will appear here](/trials/$1)");
        text = text.replace(/:-\)/g, '☺');
        text = text.replace(/:-\(/g, '☹');
        text = text.replace(/:flower:/g, '⚘');
        text = text.replace(/:heart:/g, '❤');
        text = text.replace(/:star:/g, '★');
        text = text.replace(/:rose:/g, '❀');
        text = text.replace(/:music:/g, '♫');
        return text.replace(/(^|[\s\(])(NCT[0-9]{8})($|[\s\)])/gi, "$1[$2](/trials/$2)$3");
      });
      root.editor = new Markdown.Editor(converter);
      root.editor.run();
    }
  
  }).call(this);
</script>




</body>
</html>
